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ABBREVIATIONS 
 
APL                           Acute promyelocytic leukemia  
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ATO                           Arsenic trioxide 
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Bcl-2                           B-cell lymphoma 2 
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CML                           Chronic myelogenous leukemia  
CQ                            Chloroquine diphosphate  
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LC3                           Microtubule-associated protein 1A/1B-light chain 3  
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RTS                            Realgar transforming solution  
TBST                          Tris buffered saline with Tween 
TGP                            Thermo-reversible gelatin polymer  
2D                             Two-dimentional  
3D                             Three-dimentional  
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INTRODUCTION  
 
Arsenic compounds are regarded as therapeutic agents for both external and internal use [1]. 
The medicinal application of arsenic compounds can be dated back more than 2000 years to 
ancient China and Europe. Arsenic and arsenic salts have been effectively used as key ingredients 
in treatment of plague, malaria, inflammation, ulcers, convulsions, schistosomiasis, and cancer [2, 
3]. Arsenic’s utility as an anticancer agent was first reported in the 18th century in the treatment of 
different types of leukemia [4]. Because of the emerging of novel chemotherapeutic regimens and 
therapies, the use of arsenic compounds for anticancer treatments has been declined for a long 
time [4]. In early 1970s, arsenic trioxide (ATO), a trivalent arsenic compound, was reported for its 
successful treatment of acute promyelocytic leukemia (APL) in China [5]. Since 2000, ATO has 
been approved by FDA for its application as the standard of care for relapsed APL, which has 
resulted in remission rates of over 80% as a single agent [6].  
Over recent decades, accumulating studies have shown the efficacy of arsenic compounds, 
such as ATO and sodium arsenite, in the treatment of different types of carcinoma including breast 
cancer [7-11]. However, such arsenics are commonly regarded as toxic compounds which are 
associated with adverse effects such as visceral organ damage, serious acute toxicity, and potential 
carcinogenicity, especially in long-term use [12, 13]. Accordingly, these agents are limited in the 
clinical applications especially in consolidation and maintenance therapy [14]. Therefore, an 
alternative agent with similar therapeutic efficacy but much fewer adverse effects is urgently 
required to be developed. Such agent would provide an optimized balance of cost-effectiveness, an 
improved quality of life, a better tolerance, as well as an easy access to consolidation and 
maintenance remedies [15]. In consequence, arsenic disulfide (As2S2), a main active ingredient of 
orange-red crystalline realgar, also known as ‘Xiong-Huang’ in traditional Chinese medicine, was 
chosen to be a candidate for its good therapeutic reputation and relatively low toxicity in the 
treatment of various types of malignancies.  
Realgar, containing 90% arsenic disulfide (As2S2, or named as tetra-arsenic tetra-sulfide), is a 
red, semiconductor, arsenic mineral that exists in several crystalline forms [16-18]. At least two 
polymorphs of As2S2 (sometimes referred as As4S4 or AsS) have been reported, and both forms are 
based on the same cage-like molecule [16, 18]. α-As2S2, a low-temperature phase, is termed as 
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natural realgar or mineral realgar, whereas, β-As2S2, a high-temperature phase, can be obtained by 
heating realgar above 260℃ or by high-energy milling [16, 18, 19]. The β-phase is stable and 
slowly reconverts to the α-phase upon cooling. Upon exposure to visible light, both α- and β-phase 
are transformed from red materials into bright yellow pararealgar [18, 20]. Realgar has been 
applied clinically in China for more than 1800 years in treatment of various diseases [21]. The 
first medicinal application of realgar can be traced back to 200 BC in Shen Nong Ben Cao Jing 
(神农本草经, the first Chinese Materia Medica), in which realgar was historically recorded to 
treat skin diseases [3, 22]. As summarized in the Chinese Pharmacopeia (2010 edition), during 
centuries of medicinal history, realgar was used both externally and internally in treatment of 
carbuncles, scalds and burns, insect-bites, abdominal pain induced by parasitic infestation, 
infantile convulsions, convulsive epilepsy, and malaria [22].  
In recent years, clinical trials have shown the promising anticancer efficacies of realgar 
especially in treatment of refractory or relapsed APL and chronic myelogenous leukemia (CML) 
[23, 24]. Of note, it has been reported that a single agent realgar could induce the complete 
remission, prolonged disease-free survival, and tolerable side effects in patients with newly 
diagnosed and relapsed APL [14, 15]. Orally administered realgar has been reported to be highly 
effective and safe for both remission induction and maintenance in all stages of APL [14, 15]. In 
1960s, realgar was firstly applied clinically to treat leukemia, in particular chronic myelocytic 
leukemia (CML), in the form of realgar-containing formulae namely Qinghuang Powder (QHP), 
which consists of realgar and natural indigo, resulting in high complete remission rates in CML 
patients [22, 25]. In 1980s, QHP and a similar realgar-containing formulae Realgar-Indigo 
naturalis formula (RIF) were used in treatment of APL, and led to high clinical complete 
remission rate for APL patients [25-27]. Furthermore, realgar-containing formulae also have been 
clinically applied to treat other hematological tumors, such as myelodysplastic syndrome (MDS) 
and multiple myeloma (MM) [25, 28, 29]. In the case of single use of As2S2 for treatment of 
leukemia, a clinical pilot trial involving a total of 129 patients with APL at different disease stages 
has shown, for the first time that oral administration of As2S2 leads to encouraging therapeutic 
efficacies in both remission induction and maintenance with tolerable side effects in all stages of 
APL [30]. Clinical pharmacokinetic studies demonstrated that the single dose of up to 60 mg/kg 
As2S2 was well tolerated. Arsenic could be detected in the blood 30 minutes after oral 
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administration of As2S2. A single large dose of arsenic sulfide in 7 patients with APL produced 
similar and tolerable peak blood arsenic levels. Both blood and urinary arsenic levels declined 
after As2S2 was discontinued, since around 70% of absorbed arsenic is excreted in urine by means 
of kidneys. In addition, arsenic binds keratoprotein and can be removed via hair and nail growth 
and cutaneous surfaces [14]. It has been recommended that As2S2 as a single agent could be used 
as a second-line chemotherapeutic remedy for the treatment of APL [22], though its clinical 
application in Japan is not approved. 
It has been shown that the anticancer action of As2S2 is not specific in treatment of leukemia, 
but is also observed in treatment of various solid tumors. Liu et al. have investigated the effects of 
nanometer realgar suspension on proliferation and apoptosis of human uterine cervix cancer cell 
line SiHa cells. They have found that nanometer realgar suspension inhibited the proliferation and 
induce apoptosis of SiHa cells [31], which may be related to the down-regulation of HPV16E6/E7 
gene expression. Cheng et al. have explored the molecular mechanism of realgar-induced 
apoptosis of cervical cancer cells. They have found that the induction of apoptosis by realgar is 
mediated through a cytochrome c-dependent pathway, which sequentially activates caspase-9 and 
caspase-3 [32]. Ding et al. have reported that As2S2 had the in vitro growth inhibitory activity 
against different human solid tumor cell lines, including MKN45 gastric cancer cell line, A375 
malignant melanoma cell line, 8898 pancreatic carcinoma cell line and HepG2 hepatocellular 
carcinoma cell line, but produced a less pronounced effect on human normal liver L02 cells [2]. 
Zhao et al. have shown that realgar nanoparticles induced antitumor activity in human 
osteosarcoma cell line MG-63 and hepatoma carcinoma cell line HepG-2, but exhibited slight 
cytotoxicity to L-02 cells [24]. Song et al. have shown that realgar transforming solution (RTS) 
had a strong activity inducing apoptosis and interrupting G2/M progression in human 
hepatocellular carcinoma HepG2 cells via up-regulation of cellular reactive oxygen species (ROS) 
expression [33]. Zhao et al. have found that realgar significantly suppressed the proliferation and 
induced apoptosis in B16 melanoma cells in a dose-dependent manner [23]. In addition, the results 
demonstrated that realgar nanoparticles can be dermally delivered to achieve high efficacy and 
low toxicity against melanoma in vivo [23]. Pastorek et al. have shown that realgar nanoparticle 
treatment at lower and higher drug concentrations of As2S2 induced dose-dependent activation of 
autophagy and apoptosis respectively in human melanoma cell lines BOWES and A375 [34]. Wu 
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et al. have found the significant in vitro and in vivo cytotoxic effects of nanosized realgar particles 
on selected human ovarian (C180-13S, OVCAR, OVCAR-3) and cervical (HeLa) cancer cell lines 
and rats [15], which were caused by apoptosis as confirmed by cell cycle and DNA laddering 
analysis. In in vivo study, a remarkable increase in urinary recovery of arsenic was observed in 
rats after a single oral administration of the cryo-ground realgar particle suspension [15].  
Although the cytocidal effect of As2S2 in a series of solid tumor cells has been demonstrated as 
mentioned above, a limited number of studies have reported the cytotoxic effect of As2S2 in 
human breast cancer [35], which is one of the most common female malignancies, as well as one 
of the leading causes of cancer-associated morbidity and mortality in women [36, 37]. In addition, 
there has been rare case of studies investigating the underlying mechanisms of the effects of As2S2 
against breast carcinoma. Therefore, the present study aimed to investigate the effects of As2S2 on 
human breast cancer cell lines and to further disclose the possible molecular mechanisms 
underlying the action of the drug.  
The present study showed that As2S2 exerted a much less cytotoxic effect on human normal 
breast cell line in comparison with breast cancer cells. In addition, I also investigated the 
synergistic anticancer effects of As2S2 with low concentration combined with DL-buthionine-(S, 
R)-sulfoximine (BSO), a potent specific inhibitor of glutathione (GSH) biosynthesis, on breast 
cancer cells in both 2D- and 3D-cultured systems so as to maximize the therapeutic efficacies and 
minimize the toxicities of As2S2. Moreover, the possible mechanisms of the synergistic antitumor 
activities were also investigated.  
 
The present study mainly consists of three parts as follows: 
1. Anticancer efficacies of As2S2 on human breast cancer cells cultured in two‑ and 
three‑dimensional systems. Comparison of As2S2 induced cytotoxicity between human normal 
breast epithelial cells and human breast cancer cells. 
2. Anticancer efficacies of As2S2 on breast cancer cells and their underlying molecular 
mechanisms. 
3. Synergistic anticancer effects of As2S2 in combination with BSO on breast cancer cells.  
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CHAPTER ONE 
Anticancer efficacies and underlying mechanism of action of arsenic disulfide on breast 
cancer cells in different culture systems 
  
SECTION ONE 
Anticancer efficacies of arsenic disulfide on breast cancer cells cultured in two‑ and three‑
dimensionally systems  
 
1. INTRODUCTION 
In recent decades, studies on the development of three dimensional (3D) cell culture systems 
to generate multicellular tumor spheroids have been attracted much attention. The findings of such 
studies suggest that the growing cancer cells in 3D culture mimics more closely the in vivo 
environment compared with traditional two dimensional (2D) cell culture systems [38-41]. In this 
sense, 3D cultured breast cancer cells are able to provide more accurate drug efficacies in 
development of novel therapeutics [38]. The actual tumor microenvironment in the human body 
consists of cancer cells, fibroblasts, endothelial cells and extracellular matrix [39]. In comparison 
with 2D cell culture systems, the specific characteristics of 3D culture systems include tight 
cell-cell interactions, cell-microenvironment interactions, and special internal and external cellular 
structures [40, 41].  
The aim of this section was to compare the effects of As2S2 between 2D and 3D cultured 
breast cancer cells, and to further disclose the possible molecular mechanisms underlying the 
action of this drug.  
 
2. MATERIALS AND METHODS 
2.1  Reagents 
Cell counting kit-8 (CCK-8) was obtained from DOJINDO Laboratories (Tokyo, Japan). 
Fluorescein isothiocyante (FITC) Annexin V Apoptosis Detection Kit was purchased from BD 
Biosciences (San Diego, CA, USA). ECL™ Western Blotting Analysis System and ECL™ Prime 
Western Blotting Detection Reagent were purchased from GE Healthcare (Buckinghamshire, UK). 
As2S2 and mouse anti-human Bax were purchased from Sigma (St. Louis, MO, USA). 
Pro-Survival Bcl-2 Family Antibody Sampler Kit, rabbit anti-human PI3 Kinase, rabbit 
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anti-human Akt, and rabbit anti-human mTOR were obtained from Cell Signaling (Danvers, MA, 
USA). Mouse anti-human Caspase-7 was purchased from BD Pharmingen (San Jose, CA, USA). 
Mouse anti-human p53 was obtained from BioLegend (San Diego, CA, USA). 
 
2.2  Cell line and cell culture 
MCF-7 cell line was purchased from the American Type Culture Collection (Manassas, VA, 
USA) and cultured in minimum essential medium-alpha (MEM-α) medium (Gibco, Grand Island, 
NY, USA) supplemented with penicillin, streptomycin and 10% fetal bovine serum (Sigma, St. 
Louis, MO, USA). Cells were maintained as attached cells at 37°C in 5% carbon dioxide in a 
humidified atmosphere.   
 
2.3  2D cultured cells 
MCF-7 cells were seeded at a density of 1×104 cells per well in 500 μl of cell culture media 
into 48-well plates (IWAKI), and then incubated overnight, then followed by drug treatment, 
cytotoxicity assay and other downstream applications, including apoptosis detection and Western 
blotting.  
 
2.4  3D cultured cells 
Three-dimensional spheroids were formed by using 48-well DSeA 3D micro-plates 
(International Frontier Tehnology, IFTL, Tokyo, Japan) with thermo-reversible gelatin polymer 
(TGP) [42]. Briefly, TGP powder in each well was dissolved in MEM-α medium and incubated at 
4°C overnight to develop the aqueous solution (sol phase). MCF-7 cells were then seeded into 
cold MEM-α medium with TGP on ice at a density of 1×104 cells per well, followed by incubation 
at 37°C to develop the gel form. MCF-7 cells were incubated in the gel at 37°C for 72 h to 
develop the full- fledged spheroids (Figure 1-1-1).  
 
2.5  Microscopy 
The cellular morphological structures of MCF-7 cells in 2D- and 3D-cultures were observed 
on the fourth day after seeding using an IX70® inverted microscope (Olympus, Tokyo, Japan). A 
series of bright field images were recorded and examined with 10×, 20× and 40× objectives 
12 
 
(original magnifications: 100×, 200×, and 400×, respectively). 
 
2.6  Cytotoxicity assay 
Cell cytotoxicity was analyzed by CCK-8 assay. For MCF-7 cells, 1×104 cells per well were 
seeded into 2D- and 3D-cultured 48-well plates, respectively. The stock solution of 0.6 mM As2S2 
was prepared as previously described by Hu et al. [43]. After an overnight incubation, vehicle (cell 
culture media) for control and different concentrations of As2S2 were added into the corresponding 
wells of both 2D and 3D plates to adjust the final drug concentrations of 0-24 μM. The cells were 
allowed to grow for 72 h at 37°C. CCK-8 solution (25 µl) was subsequently added into each well, 
followed by additional incubation for 3 h at 37°C. The OD value of each well was measured by a 
micro-plate reader (Corona MT P-32; Corona Co., Hitachi, Ibaraki, Japan) at 570 nm. The cell 
viability rate was calculated according to the following formula: 
Cell viability rate = (OD sample value – OD blank value) / (OD control value – OD blank value) × 
100%.  
 
2.7  Assessment of apoptosis  
The apoptotic rate in culture of MCF-7 cells was analyzed by an Annexin V- FITC Apoptosis 
Detection Kit. One ml of MCF-7 cell suspension (2×105 cells/ml) was seeded in 24-well plates, 
and then treated with serial concentrations (0, 4, 8, and 16 µM) of As2S2 for 72 h. Subsequently, 
the staining procedure was performed according to the manufacturer’s instructions. A total of 
1×104 cells were analyzed using a flow cytometer (BD Biosciences, CA, USA). The cells were 
subsequently assessed for viable (Annexin V-/PI-), early apoptosis (Annexin V+/PI-), late 
apoptosis (Annexin V+/PI+) and necrosis (Annexin V-/PI+) cells.  
 
2.8  Western blot analysis 
Western blotting was carried out to evaluate the protein amounts of B-cell lymphoma 2 (Bcl-2), 
Bcl-2 associated x protein (Bax), p53, caspase-7, phosphatidylinositol 3- kinase (PI3K), Akt, and 
mammalian target of rapamycin (mTOR) in both monolayers (2D) and spheroids (3D). Total 
proteins were extracted from the MCF-7 cells that treated with 0, 4, 8 and 16 µM As2S2 in both 2D 
and 3D cell culture systems. Briefly, proteins were separated by SDS-PAGE and transferred into 
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polyvinylidene difluoride (PVDF) transfer membranes (Immobilon-P, Darmstadt, Germany). The 
membranes were blocked with skimmed 5% milk for 1 h. The membranes were washed with 
TBST and then incubated overnight at 4°C with 1:500 anti-mouse p53 specific antibody 
(BioLegend, 628201), 1:500 anti-mouse Bax specific antibody (Sigma, B8429), 1:1000 
anti-mouse caspase-7 specific antibody (BD Pharmingen, 551238), 1:1000 anti-rabbit Bcl-2 
specific antibody (Cell Signaling, 9941), 1:1000 anti-rabbit PI3K p85 specific antibody (Cell 
Signaling, 4228), 1:1000 anti-rabbit Akt specific antibody (Cell Signaling, 4691), and 1:1000 
anti-rabbit mTOR specific antibody (Cell Signaling, 2983). Membranes were also probed with 
mouse anti-human beta-actin (abcam, ab49900) at 1:4000 dilutions as the internal control. The 
membranes were incubated overnight with the primary antibodies listed above at 4℃. On the next 
day, the membranes were incubated with anti-mouse or anti-rabbit specific polyclonal secondary 
antibodies for 1 h at room temperature. The membranes were washed three times with TBST. 
Signals were detected with an ECL Western Blot detection kit in a luminescent image analyzer 
(Fujifilm, LAS-3000, Tokyo, Japan). The images obtained were subsequently quantitatively 
analyzed with the ImageJ software program (Rasband, W.S., ImageJ, U. S. National Institutes of 
Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/).  
 
2.9  Statistical analysis 
The data are presented as the mean ± SEM. A one-way analysis of variance (ANOVA) 
followed by Tukey’s post-hoc test was performed for multiple comparisons. Student’s t-test was 
used for the comparison of two groups. P values less than 0.05 were considered to indicate 
statistical significance. Each experiment was repeated independently at least three times. 
 
3 RESULTS 
 
3.1  Microscopic imaging of 2D- and 3D-cultured MCF-7 cells. 
After treatment with 0, 4, 8 and 16 µM As2S2 for 72 h, the bright field images of MCF-7 cells 
in both 2D and 3D cultures were perceptibly recorded using an inverted microscope (Olympus, 
Japan) with original magnifications of 100×, 200×, and 400× (objectives: 10 ×, 20 × and 40 ×, 
respectively).  
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As shown in Figure 1-1-2, MCF-7 cells in the 2D culture plates simply attached to the bottom 
of the wells in a monolayer manner, while they formed multicellular spheroids (MCS) in the 3D 
culture plates. The morphological changes of MCF-7 cells cultured as 2D monolayers and 3D 
spheroids following exposure to 0, 4, 8 and 16 µM As2S2 were examined. Exposure to a relatively 
high concentration (8 or 16 µM) of As2S2 caused substantial morphological defects in both 2D and 
3D culture systems. In detail, after treatment with As2S2 for 72 h, the MCF-7 monolayers in the 
2D plates obviously decreased in a dose-dependent manner, while the structural integrity of the 
MCF-7 spheroids in the 3D plates deteriorated and fragmented with a destructive configuration. In 
contrast, treatment with 4 µM As2S2 led to a modest decrease in 2D-cultured MCF-7 cells, 
whereas it failed to cause any morphological changes in 3D spheroids. 
 
 
Figure 1-1-1  Schematic diagrams of 3D cell culture system. (A) In a 3D plate, TGP was 
dissolved in MEM-α medium and incubated at 4°C overnight to develop the aqueous solution (sol 
phase). (B) MCF-7 cells were seeded into cold MEM-α medium with TGP (sol phase) on ice, 
followed by the incubation at 37°C for 1 h to develop the gel form. Additional warm MEM-α 
medium was then added to cover the top of the gel. (C) The MCF-7 cells were incubated in the gel 
overnight at 37°C for 72 h to develop full- fledged spheroids. 
        
15 
 
 
Figure 1-1-2  The different morphology of MCF-7 cells in 2D and 3D cultures and their 
changes following exposure to As2S2. MCF-7 cells were seeded at the density of 1×104 cells per 
well in 2D- and 3D-cultured systems, respectively. Subsequently, the cells were treated with 0, 4, 
8, and 16 µM As2S2 for 72h. Bright field images of MCF-7 monolayers and spheroids were 
acquired using an IX70® inverted microscope (Olympus, Japan), with 10×, 20× and 40× 
objectives (original magnifications, 100×, 200×, 400×, respectively). Scale bar represents 1 mm.  
 
3.2  The cytotoxic effects of As2S2 on 2D- and 3D-cultured MCF-7 cells. 
CCK-8 assays were performed to assess the viabilities of 2D- and 3D-cultured MCF-7 cells 
exposed to 0-24 µM of As2S2 for 72 h. As shown in Figure 1-1-3A, a significant decrease in cell 
viability was observed in 2D-cultured cells after treatment with various concentrations of As2S2; 
this occurred in a dose-dependent manner. In detail, in comparison to the control group (0 µM 
As2S2), cell viability was significantly reduced to 77.3 ± 3.9 % and 15.2 ± 1.0 % after exposure to 
2 and 24 µM As2S2, respectively. In contrast, relatively higher concentrations (≥ 8 µM) of As2S2 
were required to show significant dose-dependent inhibitory effects on 3D-cultured MCF-7 cells. 
There were significant differences between the 2D- and 3D-cultured systems in cell viability 
following exposure to As2S2 with the final drug concentrations of 4, 8, 12, and 16 µM (P < 0.01). 
Although similar dose-dependent growth inhibition was observed in 3D-cultured MCF-7 cells, the 
growth inhibition rates were much lower than those observed in the 2D culture system. In 
particular, the growth inhibition rates induced by a relatively high concentration (≥ 8 µM) of 
As2S2 in 2D culture system were more than two times higher than those observed in the 3D culture 
system, indicating that the MCF-7 spheroids in the 3D culture system were more resistant to the 
cytotoxicity of As2S2 in comparison to the monolayers in the 2D culture system.  
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Figure 1-1-3  Effects of As2S2 on viabilities of MCF-7 cells in 2D (open symbol) and 3D 
(closed symbol) culture systems. Cells were cultured with 0, 2, 4, 8, 12, 16, 20, and 24 µM As2S2 
for 72h, and the cell viabilities were assessed by WST assays. (A) Cell viabilities of MCF-7 
monolayers (2D) and spheroids (3D) following exposure to different concentrations of As2S2. (B) 
Dose response curves for the inhibitory effects of As2S2 on the cell viabilities of 2D-cultured (〇) 
and 3D-cultured (●) MCF-7 cells. (C) The mean IC50 values of As2S2 on MCF-7 cell viabilities in 
2D and 3D culture systems. All of the data were expressed as the mean ± SEM (n ≥ 3). 
Asterisks indicate significant differences between control and drug treatment groups (**P < 0.01 
and ****P < 0.0001). Hashes indicate significant differences between 2D and 3D cultured cells 
(##P < 0.01 and ###P < 0.001). 
 
The growth inhibition curves were obtained using the probit regression analysis method 
(Figure 1-1-3B), and the half-maximal inhibitory concentration (IC50 value) of As2S2 in 2D and 
3D culture systems was further calculated from their respective inhibition curves. As shown in 
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Figure 1-1-3C, the mean IC50 value of As2S2 in the 3D culture system was approximately 3 times 
higher than that in the 2D culture system (5.1 ± 0.7 µM in 2D culture system vs. 15.7 ± 2.1 µM in 
3D culture system; P = 0.0091). Apparently, the monolayer cells were more sensitive to As2S2 in 
comparison to the spheroid cells.  
 
3.3  As2S2-induced apoptosis in 2D- and 3D-cultured MCF-7 cells. 
MCF-7 cells of monolayers and spheroids were exposed to 0, 4, 8, and 16 µM As2S2 for 72 h, 
and the number of apoptotic MCF-7 cells was measured by Annexin V-FITC/PI dual staining 
assay, followed by flow cytometry. MCF-7 cells in early (Q4) and late apoptosis (Q2) were 
differentially detected (Figure 1-1-4A).  
 
Early apoptosis (Figure 1-1-4B and C) 
As shown in Figure 1-1-4B, the early apoptosis in MCF-7 cells was induced by As2S2 in a 
dose-dependent manner in both 2D culture and 3D culture systems. Without any drug exposure, 
MCF-7 cells in 3D culture seemed to be more susceptible to early apoptosis than those in 2D 
monolayers. The median values of Annexin V+/PI- (early apoptosis) cells in the 2D monolayers 
and the 3D spheroids were 6.7 ± 1.6 % and 19.7 ± 1.8 %, respectively. The number of early 
apoptotic cells in drug-free 3D culture was significantly higher in comparison with that in 2D 
culture (P = 0.0017). Following treatment with 4, 8 and 16 µM of As2S2 for 72 h in 2D culture 
monolayers, the percentages of cells in early apoptosis were 13.4 ± 3.3 % (P = 0.5439), 22.4 ± 5.2 % 
(P = 0.0340), and 31.1 ± 2.9 % (P = 0.0017), respectively, in comparison to control (0 µM As2S2). 
Whereas, following treatment with 4, 8 and 16 µM of As2S2 for 72 h in 3D culture spheroids, the 
percentages of cells in early apoptosis were 25.6 ± 2.0 % (P = 0.1628), 30.2 ± 2.3 % (P = 0.0082), 
and 34.6 ± 1.1 % (P = 0.0005), respectively, in comparison to control.  
In the absence of As2S2, the 3D spheroids were more susceptible to early apoptosis in 
comparison to 2D monolayers. We therefore compared the pro-early apoptotic effects of As2S2 
between 2D and 3D systems by evaluating the apoptotic index, namely, the ratio of apoptotic cell 
percentages between the drug-treated cells and the control cells. As shown in Figure 1-1-4C, the 
early apoptotic indices in the 2D-cultured MCF-7 cells treated with 4, 8 and 16 µM of As2S2 for 
72 h increased 2.2 ± 0.5-folds (P = 0.8209), 4.0 ± 1.2-folds (P = 0.2107), and 5.7 ± 1.5-folds (P = 
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0.0275), respectively, in comparison to control (1.00). In 3D-cultured spheroids, the early 
apoptotic indices after treatment with 4, 8 and 16 µM of As2S2 increased 1.3 ± 0.2-folds (P = 
0.4645), 1.6 ± 0.2-folds (P = 0.0988), and 1.8 ± 0.2-folds (P = 0.0140), respectively, in 
comparison to control (1.00). These data demonstrated that MCF-7 cells cultured as spheroids 
were more resistant to As2S2 in terms of the early induction of apoptosis, in comparison to cells 
cultured as monolayers, with statistically significant differences in the presence of 8 µM (P = 
0.0457) and 16 µM (P = 0.0448) As2S2.  
 
Late apoptosis (Figure 1-1-4D and E) 
As shown in Figure 1-1-4D, late apoptosis in MCF-7 cells was induced by As2S2 in a 
dose-dependent manner, especially in 2D monolayers. In 2D culture monolayers, after treatment 
with 4, 8 and 16 µM of As2S2 for 72 h, the percentages of cells in late apoptosis (Annexin V+/PI+) 
were 0.5 ± 0.2 % (P = 0.9568), 1.2 ± 0.6 % (P = 0.3166), and 3.6 ± 0.1 % (P = 0.0005), 
respectively, in comparison to control. In contrast, the MCF-7 spheroids were more resistant to 
As2S2-induced late apoptosis, without any significant increases in those cells in the presence of 
any concentration of As2S2. 
As shown in Figure 1-1-4E, the late apoptotic index of MCF-7 cells was induced by As2S2 in a 
dose-dependent manner in both 2D culture and 3D culture systems. In 2D-cultured monolayers, 
following treatment with 4, 8 and 16 µM As2S2 for 72 h the late apoptotic index increased 2.7 ± 
0.5-folds (P = 0.8894), 4.5 ± 0.5-folds (P = 0.5016), and 9.0 ± 4.5-folds (P = 0.0458), respectively, 
in comparison to control (1.00). In the 3D-cultured spheroids, following As2S2 treatment at 
concentrations of 4, 8 and 16 µM for 72 h, the late apoptotic index increased 1.0 ± 0.4-folds (P > 
0.99), 1.7 ± 0.4-folds (P = 0.5419), and 2.6 ± 0.4-folds (P = 0.0352), respectively, in comparison 
to control (1.00). Thus, our data demonstrated that MCF-7 cells cultured as spheroids were more 
resistant to As2S2 in terms of the late induction of apoptosis, in comparison to cells cultured as 
monolayers, with statistically significant differences in the presence of 4 µM (P = 0.0206) and 8 
µM (P = 0.0231) As2S2, respectively.  
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Figure 1-1-4  As2S2 induces apoptosis in 2D- and 3D-cultured MCF-7 cells.  MCF-7 
monolayers (2D) and spheroids (3D) were treated with 0, 4, 8, and 16 µM As2S2 for 72h, and early 
and late apoptosis were examined. (A) A dot-plot analysis of 2D- and 3D-cultured MCF-7 cells 
treated with As2S2. MCF-7 cells treated with 0, 4, 8, and 16 µM As2S2 were stained with Annexin 
V/PI and analyzed by flow cytometry. Cells were classified into four groups based on different 
quadrants: viable cells (Q3), early apoptotic cells (Q4), late apoptotic cells (Q2), and necrotic cells 
(Q1). (B) and (C) show the data for early apoptotic MCF-7 cells induced by As2S2 in 2D (open 
bars) and 3D (closed bars) culture systems. (D) and (E) show the data for late apoptotic MCF-7 
cells induced by As2S2 in 2D and 3D culture systems. (B) and (D) show the apoptotic cell 
percentages, while (C) and (E) show their indices calculated as relative values in comparison to 
control (see Results). All data were expressed as the mean ± SEM (n ≥ 3). Asterisks indicate 
significant differences between the control and drug treatment groups (*P < 0.05, **P < 0.01, and 
***P < 0.001). Hashes indicate significant differences between 2D and 3D culture systems (#P < 
0.05 and ##P < 0.01). 
20 
 
3.4  Effects of As2S2 on the expression of apoptosis-related proteins in 2D- and 3D-cultured 
MCF-7 cells. 
To further investigate the mechanism underlying the As2S2-induced apoptosis in MCF-7 
monolayers and spheroids, the expression levels of pro-apoptotic and anti-apoptotic proteins were 
assessed by Western blotting. As shown in Figure 1-1-5A, C, and D, the expression levels of 
pro-apoptotic proteins Bax, p53 and caspase-7 were significantly upregulated by As2S2 in MCF-7 
monolayers. The protein levels of Bax were markedly increased after treatment with 4 (P = 0.004), 
8 (P = 0.0032) and 16 µM (P = 0.0258) As2S2, as compared to control (0 µM As2S2) (Figure 
1-1-5A).  p53 protein level increased in a dose dependent manner following exposure to 4, 8, and 
16 µM As2S2, and statistically significant increase was observed after treatment with 16 µM As2S2 
(P = 0.0045) (Figure 1-1-5C). The protein expression of caspase-7 was significantly upregulated 
after incubation with 8 (P = 0.0003) and 16 µM (P = 0.0009) As2S2, as compared to the control 
(Figure 1-1-5D). In contrast, a similar increase in the expression level of Bax was confirmed in 3D 
spheroids after treatment by 4, 8, and 16 µM As2S2 (P = 0.0026, P = 0.0265, P = 0.0226 vs. 
control, respectively). As2S2 treatment tended to increase p53 expression, while expression of 
caspase-7 did not significantly increase in the 3D culture system (Figure 1-1-5A, C and D). 
As shown in Figure 1-1-5B, following treatment with As2S2 for 72 h, expressions of 
anti-apoptotic protein Bcl-2 were downregulated in both MCF-7 monolayers and spheroids. After 
treatment with 16 µM As2S2, statistically significant decreases were observed in MCF-7 
monolayers (P = 0.0221 vs. control) and spheroids (P = 0.0051 vs. control).  
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Figure 1-1-5  Effects of As2S2 on expression amounts of apoptosis-related proteins in 2D- 
and 3D-cultured MCF-7 cells.  Expressions of apoptosis-related proteins were analyzed by 
Western blotting. (A) As2S2 significantly increased the amounts of pro-apoptotic protein Bax in 
both MCF-7 2D monolayers and 3D spheroids. (B) As2S2 significantly reduced the amounts of 
anti-apoptotic protein Bcl-2 in MCF-7 2D monolayers and 3D spheroids in a dose-dependent 
manner. (C) As2S2 significantly increased the amounts of pro-apoptotic protein p53 in MCF-7 2D 
monolayers dose-dependently, whereas the agent slightly increased the expression of p53 in 
MCF-7 3D spheroids. (D) As2S2 significantly increased the amounts of pro-apoptotic protein 
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caspase-7 in MCF-7 2D monolayers dose-dependently, while the agent showed little effect on 
caspase-7 in MCF-7 3D spheroids. All data were expressed as the mean ± SEM (n ≥ 3). 
Asterisks indicate significant differences between the control and the drug treatment groups (*P < 
0.05, **P < 0.01, and ***P < 0.001). 
 
3.5  Effects of As2S2 on expression amounts of pro-survival proteins in 2D- and 3D-cultured 
MCF-7 cells. 
Since PI3K/Akt/mTOR pathway plays an essential role in cell growth, proliferation, and 
survival [44], the protein expression of these pro-survival mediators was analyzed in both 2D 
monolayers and 3D spheroids of MCF-7 cells. After 72 h exposure to 4, 8, and 16 µM As2S2, PI3K 
protein amounts in both 2D- and 3D-cultured MCF-7 cells decreased dose-dependently in 
comparison to their untreated counterparts (Figure 1-1-6A). 16 µM As2S2 showed a significant 
inhibitory effect on 2D monolayers (P = 0.01). As2S2 also induced significant downregulation of 
PI3K in 3D spheroids at 8 (P = 0.0066) and 16 µM (P = 0.0001), respectively. As shown in Figure 
1-1-6B, As2S2 treatment for 72 h downregulated the Akt protein expressions in both MCF-7 
monolayers and spheroids, and 16 µM As2S2 significantly decreased the protein amounts in 
MCF-7 monolayers (P = 0.0031) and spheroids (P = 0.0028). After exposure to 4, 8, and 16 µM 
As2S2, the mTOR protein amounts decreased dose-dependently in both 2D- and 3D-cultured 
MCF-7 cells in comparison to their untreated counterparts, and the 16 µM As2S2 effects were 
statistically significant in both 2D monolayers (P < 0.0001) and 3D spheroids (P = 0.0004) 
(Figure 1-1-6C). 
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Figure 1-1-6  Effects of As2S2 on expression amounts of pro-survival proteins in 2D- and 
3D-cultured MCF-7 cells.  Expression amounts of pro-survival proteins in 2D- and 3D-cultured 
MCF-7 cells were analyzed by Western blotting. (A) As2S2 significantly reduced the amounts of 
pro-survival protein PI3K in 2D monolayers and 3D spheroids in a dose-dependent manner. (B) 
As2S2 significantly reduced the amounts of pro-survival protein Akt in 2D monolayers and 3D 
spheroids in a dose-dependent manner. (C) As2S2 significantly reduced the amounts of 
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pro-survival protein mTOR in 2D monolayers and 3D spheroids in a dose-dependent manner. All 
data were expressed as the mean ± SEM (n ≥ 3). Asterisks indicate significant differences 
between the control and the drug treatment groups (**P < 0.01, ***P < 0.001, and ****P < 
0.0001). 
 
4. DISCUSSION 
In this section, an in vitro cell culture system was adopted to create 3D spheroids of MCF-7 
cells. The 3D cell culture system was based on the adoption of TGP, in which the sol/gel transiting 
phase is reversibly regulated by temperature [45]. The results demonstrated that As2S2 decreased 
the cellular viability of MCF-7 cells by inducing cellular apoptosis in both 2D and 3D cell cultures. 
These effects were also associated with activation of pro-apoptotic signals such as executioner 
caspase-7, p53, and Bax, and inhibition of Bcl-2 which is associated with anti-apoptotic signaling, 
as well as attenuating the pro-survival PI3K/Akt/mTOR pathway. In addition, the microscopic 
observations revealed that 2D cells simply attach to the bottom of the wells with traditional 
monolayer cell distribution, whereas the 3D cells form multicellular spheroids via cell-cell 
interactions. The data from the cell viability assays and apoptosis detection experiments revealed 
that 3D spheroids exhibited a certain degree of drug resistance, in comparison with the 2D 
monolayers. This could be attributed to the specific morphological structure of 3D spheroids 
(Figure 1-1-2), which is similar to the features previously reported [46, 47].  
Unregulated cell survival and uncontrolled cell growth may result in excessive cellular 
proliferation and loss of controlled cell death, which are two typical phenotypes of cancer cells [48, 
49], including breast cancer cells. As2S2 strongly inhibited the cellular viabilities of MCF-7 cells 
dose-dependently in both 2D monolayers and 3D spheroids. Consistently with these findings, the 
present data also revealed that As2S2 dose-dependently induces apoptosis in 2D- and 3D-cultured 
MCF-7 cells. Since the 3D cell culture model enables cells to form structures that mimic the in 
vivo architecture in a more physiologically relevant condition compared with traditional 2D 
monolayers [50, 51], the present study provided a possible option for investigating the function of 
As2S2 in MCF-7 cells in a novel spheroid condition. In addition, the data of this section 
demonstrated that the 3D-cultured MCF-7 cells are more resistant to the suppressive effects of 
As2S2 than the 2D-cultured MCF-7 cells. Notably, it was revealed that, in the absence of any drug 
treatment, MCF-7 cell spheroids are more susceptible to apoptosis than the 2D monolayers, which 
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is consistent with the observations reported by other researchers [52-54]. This might be associated 
with the specific hypoxic and endocrinal changes in the 3D spheroid microenvironment. This 
phenomenon was different from anoikis [55, 56], since the MCF-7 spheroids developed in the 
present study have cell-cell interactions, as well as the interaction with extracellular matrix or their 
microenvironment. 
Emerging evidence has demonstrated that arsenic compounds such as ATO exert anti-tumor 
effects by inducing apoptosis in hematological cancer and in solid tumors [57, 58]. The molecular 
mechanisms underlying arsenic-mediated apoptosis include activation of intrinsic and extrinsic 
apoptosis pathways, as well as suppression of pro-survival pathways in various cancer cell lines. 
The data of this section demonstrated that As2S2 induced the expression amounts of pro-apoptotic 
proteins and inhibited the levels of pro-survival proteins, suggesting that these effects are 
responsible for the cytotoxicity of As2S2 in MCF-7 cells. Caspases-3 and -7 play critical roles as 
effectors in the execution phase, namely, the final phase of apoptosis [59, 60]. Although the 
expression of caspase-3 was not detected in either 2D monolayers or 3D spheroids (data not 
shown), the results of the present study indicated that As2S2 significantly increased the protein 
expression of caspase-7 in 2D-cultured MCF-7 cells in a dose-dependent manner. In that respect, 
the MCF-7 cell apoptosis induced by As2S2 might be mediated via activation of caspase-7 instead 
of caspase-3, which is congruent with the findings of previous studies showing that MCF-7 cells 
do not express caspase-3, but that it may undergo apoptosis through activation of caspases-7 and 
-6 [61, 62].  
The tumor suppressor p53 is capable of inducing cell apoptosis via activation of mitochondrial 
and death receptor induced apoptotic pathways [63, 64]. My present data revealed that As2S2 
dose-dependently increased p53 protein amount in 2D-cultured MCF-7 cells, which is consistent 
with the observation that As2S2 activated caspase-7 in 2D culture. Furthermore, As2S2 activated 
Bax, a pro-apoptotic protein, but inhibited Bcl-2 which is an anti-apoptotic protein, in MCF-7 
monolayers as well as in spheroids. These results indicate a significant role of As2S2 to stimulate 
the intrinsic apoptosis pathway.  
The PI3K/Akt/mTOR pathway, which is thought to promote cellular proliferation and survival, 
and has been shown to be associated with inactivation of apoptotic signals, is the most frequently 
activated signaling pathway in breast cancer [65, 66]. Blocking the expression of PI3K/Akt/mTOR 
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simultaneously inhibits cell survival and promotes pro-apoptotic activity. The decrease in 
PI3K/Akt/mTOR expression after treatment of MCF-7 monolayers and spheroids with As2S2 
revealed a possible inhibitory role of this agent in downregulation of cancer cell survival signals, 
which suggests the activation of pro-apoptotic signaling.  
   The data of this section, in summary, provided evidence that As2S2 could be a potential 
therapeutic agent to be applied in the treatment of breast cancer. The in vitro results mentioned in 
this section suggested that As2S2 inhibited viability of MCF-7 cells and induced cell apoptosis in 
both 2D monolayers and 3D spheroids in a concentration dependent manner. Activation of 
mitochondrial apoptosis pathway is suggested to be involved in this mechanism, since the 
upregulation of pro-apoptotic mediators Bax, p53, and caspase-7, as well as downregulation of 
anti-apoptotic mediator Bcl-2 was observed following exposure to As2S2. In addition, inhibition of 
the pro-survival PI3K/Akt/mTOR pathway by As2S2 contributed to the suppression of cell 
viability and the induction of apoptosis in 2D- and 3D-cultured MCF-7 cells. Furthermore, 3D 
spheroids of MCF-7 cells had a higher rate of cell viability and reduced cell apoptosis in 
comparison with 2D monolayers following treatment with As2S2, indicating the drug resistance of 
3D spheroids. However, the present study focused on delineating the pro-apoptotic effect of As2S2 
in breast cancer cells, and therefore it was confined to one of the cell death mechanisms. Further 
studies will be performed to elucidate other potential mechanisms involved in the anti-tumor 
function of As2S2, particularly with respect to the influence on cell cycle and autophagy. The drug 
resistant mechanism of 3D spheroids is also required for further investigation. 
 
 
 
 
 
 
 
 
 
 
27 
 
SECTION TWO 
Comparison of arsenic disulfide induced cytotoxicity on cell viabilities between human normal 
breast epithelial cells and human breast cancer cells 
 
1． INTRODUCTION  
Numerous studies have supported the classification of As2S2 as a mildly toxic compound, 
which is less toxic than the common arsenic compounds arsenic trioxide, sodium arsenite, and 
arsenate [14, 67]. In addition, As2S2 can be effective after oral administration [14, 67]. Clinical 
studies and trials have proved that treatment with As2S2 could be well tolerated with only 
moderate side effects in patients suffering from acute promyelocytic leukemia [68, 69], and could 
serve as a highly effective and safe therapy in clinical practice. Accordingly, the clinical efficacy 
of As2S2 has already been established for the treatment of hematological cancer as a relatively safe 
agent [70].  
For solid tumors, previous studies have confirmed the cytotoxicity of As2S2 in various solid 
cancer cell lines including human hepatocellular carcinoma cells, cervical cancer cells, 
endometrial cancer cells, ovarian cancer cells, malignant melanoma cells, pancreatic carcinoma 
cells, and gastric cancer cells [2, 15, 31, 71, 72]. Of note, As2S2 is much less toxic to lung 
fibroblast cell line MRC-5, dermal fibroblasts (HF and Hs-68), and embryonic liver L02 cells [2, 
15, 73].  
Nevertheless, cytotoxic effects of As2S2 in treatment of normal human breast cells have been 
rarely reported before. Therefore, in this chapter, I aimed to investigate the cytotoxic selectivity of 
As2S2 in human breast cancer cells in comparison with normal human breast epithelial cells. I used 
human breast epithelial cell line 184B5 [74, 75] as a normal control, and compared the cytotoxic 
effects of As2S2 between the human breast cancer MCF-7 cells and breast normal epithelial 184B5 
cells with CCK-8 assay and fluorescent staining assays.  
 
2． MATERIALS AND METHODS  
2.1  Reagents 
As2S2 was purchased from Sigma (St. Louis, MO, USA). Calcein-acetoxymethyl ester (AM) 
and Hoechst 33342 were obtained from Molecular Probes (Eugene, Oregon, USA). CCK-8 was 
from DOJINDO Laboratories (Tokyo, Japan).  
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2.2  Cell lines and cell culture  
The human normal breast epithelial cell line 184B5 and the human breast cancer cell line 
MCF-7 were purchased from the American Type Culture Collection (Manassas, VA, USA). 
MCF-7 cells were maintained in MEM-α  medium (Gibco, Grand Island, NY, USA) 
supplemented with penicillin, streptomycin, and 10% fetal bovine serum (FBS) (Sigma). 184B5 
cells were cultured in Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12) 
medium supplemented with 5% FBS, 1× ITS (Lonza), 100 nM hydrocortisone (Sigma), 2 mM 
sodium pyruvate (Lonza), 20 ng/ml EGF (Sigma), 0.3 nM trans-retinoic acid (Sigma), 100 
units/ml penicillin and 100 µg/ml streptomycin. Both types of cells were maintained as monolayer 
attached cells or multicellular spheroids at 37°C in a humidified atmosphere with 5% carbon 
dioxide. Both cell lines used in the present study were passaged for less than 4 months after 
resuscitation.  
 
2.3  2D- and 3D-cell culture assays  
In 2D-cell culture assay, 184B5 and MCF-7 cells were seeded at a density of 1×104 cells/well 
in 500 µl cell culture media into 48-well plates (Iwaki Co., Ltd., Tokyo, Japan), respectively, 
followed by overnight incubation. In 3D-cell culture assay, 3D spheroids were formed by using 
48-well DSeA 3D micro-plates (International Frontier Technology Laboratory, Tokyo, Japan) with 
thermo-reversible gelatin polymer (TGP), according to the procedures described by Kiyomi et al. 
[42]. 184B5 and MCF-7 cells were subsequently seeded into cold MEM-α medium with TGP on 
ice at a density of 1×104 cells/well, respectively, followed by incubation at 37˚C to develop the gel 
form. Vehicle and the drug were applied in the same way as mentioned in the Section one of 
Chapter one (Materials and Methods, 2.6). After treatment with different concentrations (0-16 μM) 
of As2S2 for 72 h, cell viabilities of 184B5 and MCF-7 cells were analyzed by CCK-8 assay.  
 
2.4  Cytotoxicity assay  
Cell cytotoxicity was analyzed by using CCK-8 assay with the same operations that mentioned 
in the Section one of Chapter one (Materials and Methods, 2.6).  
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2.5  Fluorescence staining assay  
184B5 and MCF-7 cells were seeded in 2D black 96-well plates with clear bottom and 3D 
spheroid 96-well plates (CellCarrierTM-96, PerkinElmer, Massachusetts, USA) at the density of 5 
× 103 cells/well, respectively, followed by exposure to 0, 4, 6, and 8 μM of As2S2 for 72 h. Then, 
the cells were stained for 30 min in the dark at 37°C with calcein-AM and Hoechst 33342 solution, 
followed by image recording and analyses using a fluorescence micro-plate reader and Harmony 
software (Operetta CLS, PerkinElmer, Japan).     
 
2.6  Statistical analysis 
Statistical analyses were performed using software GraphPad Prism version 6.0 for Windows 
(San Diego, CA). Statistically significant differences for multiple comparisons were determined 
by one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test. Data were 
presented as means ± SEM of at least three independent experiments. P < 0.05 was considered to 
be statistically significant.   
 
3．RESULTS 
3.1  Effect of As2S2 on cell viabilities of 184B5 and MCF-7 cells in 2D-cultured system 
To investigate the effect of As2S2 on cell viabilities of 184B5 and MCF-7 cell monolayers 
(2D-cultured system), both cells were grown for 72 h in the presence of 0, 2, 4, 6, 8, 12, and 16 
μM As2S2. Then, the cell viabilities were assessed by CCK-8 assays. As2S2 significantly inhibited 
cell viabilities in a dose-dependent manner in both 184B5 and MCF-7 cells in 2D-cultured system 
(Figure 1-2-1). Of note, MCF-7 cells were significantly more sensitive to As2S2 treatment in 
comparison with 184B5 cells. As shown in Table 1-2-1, the IC50 values of As2S2 in 184B5 and 
MCF-7 cells were 12.39 ± 0.36 and 5.45 ± 0.36 μM (Mean ± SEM), respectively, showing a 
significant high sensitivity of the breast cancer MCF-7 cells to As2S2 (P = 0.0002). 
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Figure 1-2-1 Effect of As2S2 on cell viabilities of 184B5 and MCF-7 cells in 2D-cultured 
system. 184B5 (〇) and MCF-7 (●) cells in 2D-cultured system were treated with different 
concentrations of As2S2 (0-16 μM) for 72 h. Cell viability was assessed by CCK-8 assay. Data 
were presented as the mean ± SEM (n = 3). #P < 0.05, ##P < 0.01 vs. 184B5 cells in presence of 
the same concentration of As2S2.  
 
Table 1-2-1 IC50 values of As2S2 on the proliferation of different cell lines in 2D- and 3D-cultured 
systems 
  IC50 value of As2S2 (μM) 
Cell line  2D 3D 
184B5  12.39 ± 0.36 > 16 
MCF-7  5.45 ± 0.36* 8.61 ± 3.09 
Abbreviations: As2S2, arsenic disulfide; 2D, two dimensional system; 3D, three dimensional 
system. *Significantly low IC50 value (high sensitivity) was observed, as compared to the value in 
184B5 cells (P = 0.0002).  
 
3.2  Effect of As2S2 on cell viabilities of 184B5 and MCF-7 cells in 3D-cultured system 
To investigate the effect of As2S2 on cell viabilities of 184B5 and MCF-7 spheroids, both cells 
were grown for 72 h in the presence of 0, 2, 4, 6, 8, 12, and 16 μM As2S2. Then, the cell viabilities 
were assessed by CCK-8 assay. As2S2 significantly inhibited cell viabilities in a dose-dependent 
manner in MCF-7 spheroids (Figure 1-2-2), whereas the agent had little influence on 184B5 
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spheroids. As shown in Table 1-2-1, the IC50 value of As2S2 in MCF-7 spheroids was 8.61 ± 3.09 
μM (Mean ± SEM). Whereas in 184B5 spheroids, the IC50 value of As2S2 was more than 16 μM.  
 
 
Figure 1-2-2 Effect of As2S2 on cell viabilities of 184B5 and MCF-7 cells in 3D-cultured 
system. 184B5 (〇) and MCF-7 (●) cells in 3D-cultured system were treated with different 
concentrations of As2S2 (0-16 μM) for 72 h. Cell viability was assessed by CCK-8 assay. Data 
were presented as the mean ± SEM (n = 3). #P < 0.05, ##P < 0.01 vs. 184B5 cells in presence of 
the same concentration of As2S2.  
 
3.3  Effect of As2S2 on live cell number of 184B5 and MCF-7 cells in 2D-cultured system 
As an additional assay to monitor cell death, I used fluorescent markers, calcein-AM and 
Hoechst 33342, for identifying live cells and cell nucleus. As shown in Figure 1-2-3, the 
fluorescent signals obviously decreased in MCF-7 monolayers (2D-cultured system) after 
exposure to As2S2 in a dose-dependent manner. Whereas, the fluorescent signals were less affected 
by As2S2 treatment in 184B5 cells (Figure 1-2-4). In addition, I calculated the live cell number of 
both cells to quantify the selective effect of As2S2 in a more accurate way. The results showed that 
As2S2 significantly decreased the live cell numbers in both cell lines. In detail, the live cell number 
percentages (ratio to control) of 184B5 cells decreased to 74.99 ± 1.76, 75.49 ± 5.66, and 60.64 ± 
7.63 % after treatment with 4, 6, and 8 μM As2S2, respectively. In MCF-7 cells, the live cell 
number percentages (ratio to control) decreased to 42.45 ± 8.52, 28.64 ± 4.22, and 26.60 ± 3.50 % 
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after treatment with 4, 6, and 8 μM As2S2, respectively. There were significant differences of cell 
number percentages between 184B5 and MCF-7 cells after exposure to As2S2 with same 
concentration, suggesting that 184B5 cells were less sensitive to As2S2 treatment (Figure 1-2-5).  
 
 
Figure 1-2-3 Changes in fluorescent cell morphology induced by As2S2 treatment in MCF-7 
monolayers (2D-cultured system). MCF-7 cells were seeded at the density of 5,000 cells per 
well, followed by As2S2 treatment with different concentrations (0, 4, 6, and 8 µM). Viable cells 
exposed to calcein-AM (first line) showed bright green fluorescence. Hoechst staining (second 
line) as nuclear counterstain showed bright blue fluorescence. Merging (third line) of calcein-AM 
and Hoechst showed blending fluorescence. Images were taken and analyzed by a fluorescence 
micro-plate reader with a 10× objective.  
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Figure 1-2-4 Changes in fluorescent cell morphology induced by As2S2 treatment in 184B5 
monolayers (2D-cultured system). 184B5 cells were seeded at a density of 5,000 cells per well, 
followed by As2S2 treatment with different concentrations (0, 4, 6, and 8 µM). Viable cells 
exposed to calcein-AM (first line) showed bright green fluorescence. Hoechst staining (second 
line) as nuclear counterstain showed bright blue fluorescence. Merging (third line) of calcein-AM 
and Hoechst showed blending fluorescence. Images were taken and analyzed by a fluorescence 
micro-plate reader with a 10× objective.  
 
 
 
Figure 1-2-5 Effects of As2S2 on live cell number of 2D-cultured 184B5 and MCF-7 cells. 
184B5 and MCF-7 cells grown in 2D-cultured system were treated with different concentrations 
of As2S2 (0, 4, 6, and 8 μM) for 72 h. Percentages of live cell number in both 184B5 and MCF-7 
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cells were analyzed by a fluorescence micro-plate reader. Data were presented as the mean ± SEM 
(n = 3). *P < 0.05, **P < 0.01 vs. control (0 μM As2S2).  ##P < 0.01 vs. 184B5 cells in presence 
of the same concentration of As2S2.  
 
3.4  Effect of As2S2 on spheroid areas of 3D-cultured 184B5 and MCF-7 cells  
The fluorescent images showed that As2S2 treatment decreased the areas of MCF-7 spheroids 
but had little influence on 184B5 spheroids (Figures 1-2-6 and 1-2-7). These results were further 
confirmed by spheroid areas analysis. As shown in Figure 1-2-8, the spheroid area percentages 
(ratio of control) in MCF-7 cells significantly decreased to 75.80 ± 1.68 % (P < 0.0001), 65.09 ± 
0.77 % (P < 0.0001), and 61.28 ± 5.05 % (P < 0.0001) after treatment with 4, 6, and 8 μM As2S2, 
respectively. In 184B5 stained spheroids, As2S2 showed little effect on spheroid area percentages.  
 
 
 
Figure 1-2-6 Changes in fluorescent cell morphology induced by As2S2 treatment in 
3D-cultured MCF-7 spheroids. MCF-7 cells were seeded at a density of 5,000 cells per well, 
followed by As2S2 treatment with different concentrations (0, 4, 6, and 8 µM). Viable cells 
exposed to calcein-AM (first line) showed bright green fluorescence. Hoechst staining (second 
line) as nuclear counterstain showed bright blue fluorescence. Merging (third line) of calcein-AM 
and Hoechst showed blending fluorescence. Images were taken and analyzed by a fluorescence 
micro-plate reader with 5× objective.  
 
 
35 
 
 
Figure 1-2-7 Changes in fluorescent cell morphology induced by As2S2 treatment in 
3D-cultured 184B5 spheroids. 184B5 cells were seeded at the density of 5,000 cells per well, 
followed by As2S2 treatment with different concentrations (0, 4, 6, and 8 µM). Viable cells 
exposed to calcein-AM (first line) showed bright green fluorescence. Hoechst staining (second 
line) as nuclear counterstain showed bright blue fluorescence. Merging (third line) of calcein-AM 
and Hoechst showed blending fluorescence. Images were taken and analyzed by a fluorescence 
micro-plate reader with 5× objective.  
 
 
 
Figure 1-2-8  Effects of As2S2 on spheroid area of 3D-cultured 184B5 and MCF-7 cells. 
184B5 and MCF-7 cells in 3D-cultured system were treated with different concentrations of As2S2 
(0, 4, 6, and 8 μM) for 72 h. Percentages of spheroid area in both 184B5 and MCF-7 cells were 
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analyzed by a fluorescence micro-plate reader. Data were presented as the mean ± SEM (n = 3). 
**P < 0.01 vs. control (0 μM As2S2). ##P < 0.01 vs. 184B5 cells in presence of the same 
concentration of As2S2.  
 
4． DISCUSSION 
Cytotoxic effects of As2S2 on human solid tumor cell lines and the corresponding human 
normal cells have been investigated by other researchers [2, 15, 73]. All of these studies 
demonstrated that As2S2 is toxic to cancer cells but showed much less influence to normal cell 
viabilities [2, 15, 73]. However, the cytotoxic effects of As2S2 on normal human breast cells have 
been rarely reported before. In this study, I used a normal human breast epithelial cell line 184B5 
to compare the difference in sensitivity to the cytotoxic effect of As2S2 between the breast cancer 
cell line MCF-7 and the normal breast epithelial cell line 184B5 in both 2D and 3D cell culture 
systems. The results of this section showed that As2S2 exerted a cytotoxic action in both MCF-7 
and 184B5 cells in a dose-dependent manner. However, in comparison with MCF-7 cells, 184B5 
cells were less sensitive to the cytotoxic effects of As2S2, indicating the cytotoxic selectivity of 
As2S2 to human breast cancer cells as compared to human normal breast epithelial cells.  
Traditionally, 2D cell cultures have been used to evaluate the efficacies of anticancer drugs. 
However, growing evidence now shows that 2D-cultured cells have limitations to simulate some 
important characteristics of cancer cells and the microenvironment of the original tumors. The 
natural manner in which solid tumors grow in vivo is 3D, suggesting that growing cancer cells in 
3D mimics the in vivo environment better than 2D cell culture. Therefore, it is now clear that 
research has shifted into the direction of culture using 3D structures, with more realistic biological 
microenvironments. However, the field of 3D cell culture research is still in its infancy in 
comparison to the knowledge established on 2D cell culture. One major problem in the field is the 
lack of a standard approach in 3D culture, whereas 2D cell culture practice is standard and roughly 
comparable. A sensible approach for now would be to combine the traditional 2D cell culture and 
novel 3D cell culture to establish a better evaluation system for assessment of anticancer drugs 
[76-79]. Therefore, both 2D and 3D cell cultures were introduced in this study. The results show 
that As2S2 exert potent cytotoxicity on breast cancer MCF-7 cells in both 2D and 3D cell cultures, 
confirming the significant anticancer effects of As2S2 against breast cancer cells. Interestingly, 
As2S2 has some cytotoxic effects on normal breast 184B5 cells, although it is significantly less 
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toxic in comparison with the effects on MCF-7 cells. Whereas, no cytotoxic effects of As2S2 were 
observed on 3D-cultured 184B5 cells, as the structure and appearance of 184B5 spheroids were 
little affected by As2S2 treatment. Since 3D culture system mimics more closely the in vivo human 
environment in comparison with 2D culture system [38-40], the observations obtained from the 
3D system may provide more convincing evidence than those from 2D system to confirm the 
cytotoxic selectivity of As2S2 in breast cancer cells but not in normal breast epithelial cells.  
   This section thus provided an experimental confirmation for the safety of As2S2 as a relatively 
less toxic agent to normal breast cells, as well as the scientific evidence for the possible 
application of As2S2 as a potential agent in the treatment of breast cancer.  
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CHAPTER TWO 
Anticancer efficacies and underlying mechanisms of the action of arsenic disulfide on 
different breast cancer cells 
 
1． INTRODUCTION 
Numerous studies on breast carcinomas are based on in vivo and in vitro researches focusing 
on breast cancer cell lines [80, 81]. In this study, I took two typically distinctive subtypes of breast 
cancer cell lines as the research subjects, which can represent different categories of breast cancer 
disease, namely MCF-7 and MDA-MB-231 cell lines. MCF-7 is relatively a non-aggressive breast 
cancer cell line, characterized by estrogen-dependent, higher differentiated, ER-positive, and 
weakly invasive features. By contrast, MDA-MB-231 is an aggressive breast cancer cell line, 
characterized by estrogen-independent, undifferentiated, ER-negative, and highly invasive features 
[82-84]. In this study, both MCF-7 and MDA-MB-231 cell lines were taken as research objects to 
investigate the potent antitumor effects of As2S2 on breast carcinoma cells.  
As2S2 has several benefits over arsenic trioxide (ATO), including a relatively low toxicity and 
safety in oral administration, while exerting a similar antitumor effect [85, 86]. Exploring the 
antitumor effects of As2S2 against breast carcinoma might thus shed new light on the therapeutic 
potential of this arsenic compound for the treatment of breast cancer.  
Programmed cell death (PCD), which refers to any form of cell death mediated by an 
intracellular death program, plays a fundamental role in biological homeostasis [87, 88]. 
Dysregulation of this self-destructive process leads to various human diseases, including breast 
cancer. Apoptosis (type I cell death) and autophagy (type II cell death) are the two main forms of 
PCD defined based on morphological criteria [88, 89]. Apoptosis, the primary and most 
well-studied mode of programmed cell death, has been regarded as the principal pathway of PCD 
[90]. Apoptosis induction plays an essential role in anticancer chemotherapies against various 
types of cancers [91]. Autophagy is a highly regulated catabolic process that enables cells to clean 
up and degrade their own cytoplasmic components [89, 92]. Autophagy induction is attributed to 
various stresses that ultimately lead to apoptosis, and organelle dysfunction, metabolic stress, 
chemotherapies, pathogen infection, and starvation are known to induce autophagy [90]. There is a 
complex connection between apoptosis and autophagy; indeed, apoptosis may begin with 
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autophagy, and autophagy may end with apoptosis. It has been suggested that targeting both of 
these self-destructive processes may be a particularly useful chemotherapeutic strategy in the 
treatment of cancer including breast cancer [93, 94]. Accumulating evidence has shown that both 
apoptosis and autophagy can be induced by As2S2 in hematopoietic as well as solid cancer cell 
lines [34, 73, 95].  
Reactive oxygen species (ROS), as a common indicator of oxidative stress, consists of 
superoxide, hydrogen peroxide, and the hydroxyl free radical [96, 97]. ROS production by 
xenobiotics selectively kills cancer cells with negligible effects on normal cells [98]. Intriguingly, 
arsenic compounds promote the generation of ROS, and this increased ROS accumulation 
mediates the genotoxicity of arsenic in cancer cells, thereby facilitating the induction of apoptosis 
[99-101]. ROS therefore plays a pivotal role in cancer cell death caused by arsenic compounds, 
making them a tempting target for an As2S2-based strategy of cytotoxic intervention in breast 
carcinoma. 
In this chapter, the anticancer effects of As2S2 in human breast cancer cells in vitro were 
investigated and the possible underlying mechanisms involved were explored, especially with 
respect to the induction of PCD and the generation of ROS. 
 
2．MATERIALS AND METHODS  
2.1  Reagents 
As2S2, CCK-8, calcein-AM, Hoechst 33342, FITC Annexin V Apoptosis Detection Kit, 
ECLTM Western Blotting Analysis System, ECLTM Prime Western Blotting Detection Reagent, 
Rabbit anti-human matrix metalloproteinase-9 (MMP-9), Bcl-2, B-cell lymphoma-extra-large 
(Bcl-xl), caspase-7, microtubule-associated protein 1A/1B-light chain 3 (LC3A/B), cell division 
cycle protein 2 (Cdc2), mouse-anti human caspase-8, cyclin B1 and Bax were purchased from the 
same manuscripts mentioned in Section one and two in Chapter one (Materials and Methods, 2.1, 
respectively). Propidium iodide (PI), RNase A solution and 2’,7’-dichlorofluorescin diacetate 
(DCF-DA) were purchased from Sigma. Chloroquine diphosphate (CQ) was purchased from 
Wako (Osaka, Japan). 
 
2.2  Cell lines and cell culture 
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The human breast cancer cell lines MCF-7 and MDA-MB-231 were purchased from the 
American Type Culture Collection. They were cultured in MEM-α medium supplemented with 
penicillin, streptomycin and FBS (10% for MCF-7 and 15% for MDA-MB-231). The cells were 
cultured and maintained as attached cells at 37 °C in a humidified atmosphere with 5% CO2.  
 
2.3  Cell culture and treatment 
MCF-7 and MDA-MB-231 cells were seeded at 1×104 and 1.5×104 cells / well, respectively, in 
500 μl of cell culture media on 48-well plates, followed by overnight incubation. Vehicle and 
As2S2 were applied in the same way as mentioned in the Section one of Chapter one (Materials 
and Methods, 2.6). After administration with different concentrations (0-16 μM) of As2S2 for 48 h, 
cell viabilities were analyzed by CCK-8 assay.  
 
2.4  Cytotoxicity assay 
Cell cytotoxicity was analyzed by CCK-8 assay with the same operations that mentioned in the 
Section one of Chapter one (Materials and Methods, 2.6).  
 
2.5  Morphological cell viability 
MCF-7 and MDA-MB-231 cells were seeded onto a 96-well plate at 5 × 103 cells per well in 
100 µl culture medium, followed by exposure to 0, 4, 8, and 16 µM As2S2 for 48 h. The cells were 
then stained for 15 min in the dark at 37 °C with the specific live probe calcein-AM, after which 
images were measured and analyzed by a fluorescence micro-plate reader and the Harmony 
software program. 
 
2.6  Wound healing assay 
Cell migration was measured using a wound scratching assay. Cells were seeded at 4×105 cells 
per well in 6-well plates (IWAKI micro-plates) and cultured for 24 h to form a confluent cell 
monolayer. The cell layer was then scratched with a sterile micropipette tip. The cells were 
washed with phosphate-buffered saline (PBS) and incubated for 48 h in the presence of 0, 8, and 
16 µM As2S2. Images of each scratch at the same location were taken at 0 and 48 h by an IX70® 
inverted microscope (Olympus, Tokyo, Japan). Cell migration was quantified by measuring the 
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wound opening area using the ImageJ software program (Rasband, W.S., ImageJ, U.S. National 
Institutes of Health, Bethesda, MD, USA; http://rsb.info.nih.gov/ij/). 
 
2.7  Cell cycle analyses 
Both MCF-7 and MDA-MB-231 cells were seeded at 4×105 cells per well in 6-well plates 
(IWAKI micro-plates), followed by overnight incubation. Cells were treated with 0, 4, 8 and 16 
μM As2S2, followed by further 48 h incubation. Cells were harvested and then washed twice with 
PBS. Then, the cells were fixed in 70% ethanol overnight at -20 °C and stained with PI and RNase 
A solution (5 μg/ml PI, and 0.5 μg/μl RNase A). The DNA content was determined by flow 
cytometry (BD Biosciences, San Jose, CA, USA), and data were analyzed by the CellQuest 
analysis software program (ModFit LTTM Ver.3.0; Verity Software House, Topsham, ME, USA).  
 
2.8  Morphological apoptosis 
Hoechst 33342 staining was performed to observe morphological characteristics of apoptotic 
cells. MCF-7 and MDA-MB-231 cells were seeded onto a 96-well plate at 5 × 103 cells per well, 
followed by exposure to 0, 4, 8, and 16 µM As2S2 for 48 h. The cells were then stained with the 
Hoechst 33342 solution for 15 min at 37 °C in the dark. Morphological changes of cells and cell 
nucleus were observed and analyzed by fluorescence micro-plate reader and the Harmony 
software program.  
 
2.9  Assessment of apoptosis 
MCF-7 and MDA-MB-231 cells were seeded at 2×105 cells/well in 6-well plates (2 ml per 
well) and treated with serial concentrations (0, 4, 8, and 16 µM) of As2S2, followed by additional 
incubation for 48 h. The apoptotic cell rates in both cell lines were detected by FITC Annexin V 
Apoptosis Detection Kit. The staining procedure was performed according to the manufacturer’s 
instructions. Approximately 1×104 cells were analyzed using a flow cytometer (BD Biosciences, 
San Jose, CA, USA). The cells were subsequently assessed for the total number of early apoptotic 
(Annexin V+/PI-) and late apoptotic (Annexin V+/PI+) cells. 
 
2.10  Autophagy inhibition in breast cancer cells 
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To examine whether the As2S2-induced cell death was mediated through autophagy, the 
autophagy inhibitor CQ (10 µM) was added to MCF-7 and MDA-MB-231 cells 1 h prior to the 
administration of As2S2. Subsequently, 0, 4, 8, and 16 μM As2S2 was added, and the cells were 
incubated for 48 h. Then, the cell viability was assessed by CCK-8 assay.  
 
2.11  Western blot analysis 
The standard Western blot protocol was carried out in order to evaluate the protein levels of 
Bcl-2, Bax, Bcl-xl, caspase-7, caspase-8, cyclin B1, Cdc2 and LC3A/B in both MCF-7 and 
MDA-MB-231 cells. The total protein content was extracted from cells of each cell line treated by 
As2S2 at various final concentrations (0, 4, 8, and 16 µM) for 48 h. In brief, the procedures and 
operations of Western blot is the same with that described in the Section one of Chapter one 
(Materials and Methods, 2.8). Specifically, membranes were incubated overnight at 4 °C with 
1:1000 anti-rabbit MMP-9 specific antibody (whole cell lysate, abcam, ab194316), 1:1000 
anti-rabbit Bcl-2 specific antibody (Cell Signaling, 4223), 1:1000 anti-rabbit Bcl-xl specific 
antibody (Cell Signaling, 2764), 1:500 anti-mouse Bax specific antibody (Sigma, B8429), 1:1000 
anti-rabbit caspase-7 specific antibody (Cell Signaling, 12827), 1:1000 anti-mouse caspase-8 
specific antibody (Cell Signaling, 9746), 1:1000 anti-mouse cyclin B1 specific antibody (Cell 
Signaling, 4135), 1:1000 anti-rabbit Cdc2 specific antibody (Cell Signaling, 9112) and 1:1000 
anti-rabbit LC3A/B specific antibody (Cell Signaling, 12741). Membranes were also probed with 
beta-actin (Abcam, ab49900) at 1:4000 dilution as the internal control.  
 
2.12  Measurement of ROS 
MCF-7 and MDA-MB-231 cells were seeded at 4×105 cells per well in 6-well plates (IWAKI 
micro-plates), followed by overnight incubation. The cells were incubated for additional 48 h in 
the presence of 0, 4, 8 and 16 µM As2S2. DCF-DA was then added to achieve a final concentration 
of 10 μM, and the cells were incubated for 30 min in the dark at 37 °C. Subsequently, the cells 
were harvested, washed with PBS, and then re-suspended in 500 μl PBS. The intracellular ROS 
levels were analyzed using a flow cytometer (BD Biosciences, San Jose, CA, USA).  
 
2.13  Statistical analyses 
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Results were presented as the mean ± SEM of three or more independent experiments. 
Statistical analyses were performed using the GraphPad Prism software program, version 6.0 
(GraphPad Software; La Jolla, CA, USA). A one-way analysis of variance (ANOVA) followed by 
Tukey’s post-hoc test was used for multiple comparisons. P < 0.05 was considered to be 
significant.  
 
3. RESULTS 
3.1  As2S2 inhibits the cell viability of breast cancer cells.  
MCF-7 and MDA-MB-231 cells were cultured in the presence of 0-16 μM As2S2 for 48 h, and 
the proliferated viable cells were evaluated by CCK-8 assay. As shown in Figure 2-1, As2S2 
inhibited the percentages of viable MCF-7 and MDA-MB-231 cells in a dose-dependent manner. 
The IC50 values of As2S2 on the number of viable MCF-7 and MDA-MB-231 cells were 11.75 ± 
1.99 and 8.21 ± 2.07 µM after 48 h of exposure, respectively.  
 
As an alternative measurement to monitor cell growth inhibition induced by As2S2 in breast 
cancer cells, we used the fluorescent dye calcein-AM to identify live cells [102]. As shown in 
Figure 2-2 and Figure 2-3, live cell numbers in both cell lines markedly decreased after treatment 
with increasing concentrations of As2S2 in a dose-dependent manner. In MCF-7 cells, the live cell 
number, as compared to the control group of 1232.0 ± 70.7 cells, was significantly reduced to 
422.0 ± 22.9 (P < 0.0001), 291.7 ± 37.2 (P < 0.0001) and 85.0 ± 36.8 cells (P < 0.0001) after 
exposure to 4, 8, and 16 µM of As2S2 for 48 h, respectively (Figure 2-2). In MDA-MB-231 cells, 
the live cell number, compared to the control group of 1455.0 ± 68.8 cells, was significantly 
reduced to 457.0 ± 84.2 (P < 0.0001), 292.8 ± 42.2 (P < 0.0001), and 177.0 ± 11.9 (P < 0.0001) 
after exposure to 4, 8, and 16 µM of As2S2 for 48 h, respectively (Figure 2-3).  
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Figure 2-1  As2S2 inhibited viability of cells of the human breast cancer cell lines MCF-7 
and MDA-MB-231.  MCF-7 and MDA-MB-231 cells were treated with various concentrations 
(0, 4, 8, 12, and 16 µM) of As2S2 for 48 h, and the cell viability was determined by CCK-8 assay. 
Data are presented as the mean ± SEM (n ≥ 3). *P < 0.05, **P < 0.01 vs. control group 
(As2S2 0 µM).  
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Figure 2-2  As2S2-induced decrease in viable MCF-7 cells, as assessed by calcein AM and 
Hoechst 33342 staining.  MCF-7 cells were seeded at 5,000 cells per well. The cells were 
treated with serial concentrations of As2S2 (0, 4, 8 and 16 µM) for 48 h. (A) Viable cells exposed 
to calcein-AM (first line) showed bright green fluorescence. Hoechst staining (second line) as a 
nuclear counterstain showed bright blue fluorescence. Cells with bright fragmented or condensed 
nuclei (see arrows) were identified as those undergoing apoptosis. Merging (third line) of calcein 
AM and Hoechst showed cyan fluorescence. Images were taken and analyzed by a fluorescence 
Micro-plate reader (Operetta CLS; PerkinElmer, Tokyo, Japan) with a 20× objective (original 
magnification 200×). (B) A quantitative analysis of live MCF-7 cells. The ordinate represents the 
number of live cells. Data are presented as the mean ± SEM (n ≥ 3). **P < 0.01 vs. control 
group (As2S2 0 µM). 
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Figure 2-3  As2S2-induced decrease in viable MDA-MB-231 cells , as assessed by calcein AM 
and Hoechst 33342 staining.  MDA-MB-231 cells were seeded at 5,000 cells per well. The cells 
were treated with serial concentrations of As2S2 (0, 4, 8 and 16 µM) for 48 h. (A) Viable cells 
exposed to calcein-AM (first line) showed bright green fluorescence. Hoechst staining (second 
line) as a nuclear counterstain showed bright blue fluorescence. Cells with bright fragmented or 
condensed nuclei (see arrows) were identified as those undergoing apoptosis. Merging (third line) 
of calcein AM and Hoechst showed cyan fluorescence. Images were taken and analyzed by a 
fluorescence Micro-plate reader (Operetta CLS; PerkinElmer, Tokyo, Japan) with a 20× objective 
(original magnification 200×). (B) A quantitative analysis of live MDA-MB-231 cells. The 
ordinate represents the number of live cells. Data are presented as the mean ± SEM (n ≥ 3). 
**P < 0.01 vs. control group (As2S2 0 µM). 
 
3.2  As2S2 inhibits the motility of breast cancer cells. 
A scratch assay was carried out to assess the effect of As2S2 on the motility of breast cancer 
cells. As shown in Figure 2-4, with the dynamic observation at 0 and 48 h after scratching, As2S2 
treatment significantly inhibited the cell migration in both cells. In MCF-7 cells, compared with 
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the control group (0 µM of As2S2), the relative migration rates significantly decreased after 
exposure to 8 µM (P = 0.0177) and 16 µM As2S2 (P = 0.0042). In MDA-MB-231 cells, compared 
with the control group (0 µM of As2S2), the relative migration rates significantly decreased after 
exposure to 8 µM (P < 0.0001) and 16 µM As2S2 (P < 0.0001). These data show that As2S2 
inhibits the motility and invasion of different types of breast cancer cells. 
In addition, the expression of tumor migration- and invasion-related protein MMP-9 was 
analyzed by Western blot. As shown in Figure 2-5, As2S2 treatment significantly decreased the 
expression amount of MMP-9 at concentrations of 8 µM (P = 0.0446) and 16 µM (P = 0.0233) in 
MCF-7 cells in comparison with control. In contrast, in MDA-MB-231 cells, compared to the 
control, a statistically significant decrease in the expression amount of MMP-9 occurred at 16 µM 
of As2S2 (P = 0.0444). These results suggest that As2S2 exposure reduced the motility of breast 
cancer cells due, at least in part, to down-regulation of MMP-9 signals. 
 
 
Figure 2-4  Inhibitory effects of As2S2 on the migration of MCF-7 and MDA-MB-231 cells, 
assessed by a wound healing assay. (A) and (B): MCF-7 cells, (C) and (D): MDA-MB-231 cells. 
The cells were treated with 0, 8 and 16 µM As2S2 for 48 h, and then the wound areas were 
examined. (A) and (C) show representative images of wounded cells (magnification 100×). (B) 
and (D) show percentages of the relative cell migration. Data are presented as the mean ± SEM 
(n ≥ 3). *P < 0.05, **P < 0.01 vs. control (As2S2 0 µM).  
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Figure 2-5  Effects of As2S2 on MMP-9 protein expression in breast cancer cells.  MCF-7 
and MDA-MB-231 cells were treated with 0, 4, 8 and 16 µM As2S2 for 48 h. Then, Western blot 
assays were carried out to examine the effects of As2S2 on the expression of MMP-9 in both cell 
lines after 48 h of treatment. β-actin was used as an internal control. All images are representative 
of three independent analyses from three independent cellular preparations. Asterisks indicate 
significant differences between the control cells (As2S2 0 µM) and As2S2-treated cells (*P < 0.05). 
 
3.3  As2S2 triggers cell cycle arrest in breast cancer cells 
The effect of As2S2 on the cell cycle was assessed by evaluating the percentage of cells in each 
phase compared to the control in MCF-7 and MDA-MB-231 cells using PI staining and flow 
cytometry. The results indicated that As2S2 mainly induced G2/M phase arrest in both MCF-7 cells 
and MDA-MB-231 cells (Figure 2-6).   
In MCF-7 cells, after exposure to 4, 8, and 16 µM As2S2 for 48 h, the percentages of cells in 
G2/M phase significantly increased from 4.0 ± 0.8 % (0 µM) to 8.8 ± 0.5 % (P = 0.0003), 9.7 ± 
0.1% (P < 0.0001) and 12.1 ± 0.3 % (P < 0.0001), respectively. In MDA-MB-231 cells, As2S2 
treatment at 4, 8, and 16 µM for 48 h increased the percentages of cells in G2/M phase from 16.3 
± 0.4 % (0 µM) to 22.6 ± 0.3 % (P = 0.0001), 26.1 ± 0.3 % (P < 0.0001) and 43.4 ± 1.1 % (P < 
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0.0001), respectively, as well as increase in the percentages of cells in S phase from 20.4 ± 0.2 % 
(0 µM) to 23.3 ± 0.5 % (P = 0.0242), 22.9 ± 0.5 % (P = 0.0451) and 36.8 ± 0.9 % (P < 0.0001), 
respectively. 
Furthermore, the expression of cell cycle-related proteins was examined by Western blot 
analysis. As shown in Figure 2-7, compared to control, the expression amount of cyclin B1 
significantly decreased by treatment with As2S2 at concentrations of 8 µM (P = 0.0014) and 16 
µM (P = 0.0002) in MCF-7 cells. Whereas, the expression amount of cyclin B1 in MDA-MB-231 
cells increased by treatment with As2S2 at concentrations of 8 µM (P = 0.0007) and 16 µM (P = 
0.0022), respectively. After exposure to As2S2 for 48 h, a statistically significant decrease in the 
Cdc2 expression occurred in MCF-7 cells treated with 8 µM As2S2 (P = 0.0348) and in 
MDA-MB-231 cells treated with 16 µM As2S2 (P = 0.0028). 
These results suggest that As2S2 triggers G2/M phase arrest in both MCF-7 and MDA-MB-231 
cells by regulating the expression of cell cycle-related proteins.  
 
 
Figure 2-6  As2S2 triggers cell cycle arrest in breast cancer cells. (A) MCF-7 and (C) 
MDA-MB-231 cells were treated with 0, 4, 8, and 16 µM As2S2 for 48 h. The peaks in the figure 
represent G0/G1, S and G2/M phases in the cell cycle. (B) and (D) show the percentages of cells 
in a given phase of the cell cycle in MCF-7 (left) and MDA-MB-231 (right) cells after 48 h of 
As2S2 treatment. Data are expressed as the mean ± SEM (n ≥ 3). *P < 0.05, **P < 0.01 vs. 
control (As2S2 0 µM). 
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Figure 2-7  Effects of As2S2 on cell cycle regulators in breast cancer cells. MCF-7 and 
MDA-MB-231 cells were cultured with 0, 4, 8, and 16 µM As2S2 for 48 h, and Western blot assays 
were carried out to examine the effects of As2S2 on the expression of cyclin B1 and Cdc2 in both 
cell lines after 48 h of treatment. β-actin was used as an internal control. All images are 
representative of three independent analyses from three independent cellular preparations. 
Asterisks indicate significant differences between the control (As2S2 0 µM) and the drug treatment 
groups (*P < 0.05, **P < 0.01). 
 
3.4  As2S2 induces apoptosis in breast cancer cells. 
Apoptosis induced by As2S2 in MCF-7 and MDA-MB-231 was validated by Hoechst 33342 
staining and flow cytometry assay.  
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As shown in Figure 2-2 and Figure 2-3, the occurrence of typical apoptotic characteristics, 
such as cell shrinkage, chromatin condensation and nuclei fragmentation [103], appeared in both 
MCF-7 and MDA-MB-231 cells after treatment with As2S2 (8 and 16 µM) for 48 h, while normal 
nuclei manifested with a round shape and homogeneous staining was observed.  
The induction of apoptosis was further investigated by Annexin V/PI double staining assay 
followed by flow cytometry analysis. As shown in Figure 2-8A, the total proportion of apoptotic 
MCF-7 cells significantly increased from 1.1 ± 0.5 % (0 µM As2S2, control) to 6.4 ± 1.1 % (8 µM 
As2S2, P = 0.0307) and 19.4 ± 2.0 % (16 µM As2S2, P < 0.0001) after exposure to As2S2 for 48 h. 
In MDA-MB-231 cells (Figure 2-8B), the total proportion of apoptotic cells significantly 
increased from 3.7 ± 0.3 % (0 µM As2S2, control) to 6.6 ± 0.8 % (8 µM As2S2, P = 0.0345) and 
15.3 ± 1.4 % (16 µM As2S2, P < 0.0001) after exposure to As2S2 for 48 h.  
Western blotting analysis was carried out to examine the expression of apoptosis-related 
proteins. As shown in Figure 2-9, the expression of pro-apoptotic proteins, such as caspase-8 
(apoptotic initiator) and caspase-7 (apoptotic executioner), was found to be increased after 
treatment with As2S2 in a dose-dependent manner in both MCF-7 and MDA-MB-231 cells. 
Compared to the control, both caspase-7 and caspase-8 amounts in MCF-7 cells significantly 
increased after 48 h of treatment with As2S2 at 8 µM (P = 0.0234 for caspase-7 and P = 0.0158 for 
caspase-8) and 16 µM (P = 0.0129 for caspase-7 and P = 0.0391 for caspase-8). In MDA-MB-231 
cells, the amounts of caspase-7 and caspase-8 also increased significantly after 48 h of treatment 
with As2S2 at 16 µM (P = 0.0294 for caspase-7 and P = 0.0018 for caspase-8). 
As shown in Figure 2-10, the ratio of Bax expression to Bcl-2 expression increased by As2S2 
treatment in both MCF-7 and MDA-MB-231 cells. Compared to the control, significant increases 
were observed in MCF-7 cells after treatment with 8 µM (P = 0.0003) and 16 µM (P < 0.0001) of 
As2S2 for 48 h. In MDA-MB-231 cells, the ratio of Bax to Bcl-2 showed an increasing trend in a 
dose-dependent manner, although the change was not statistically significant. The anti-apoptotic 
protein Bcl-xl was inhibited by As2S2 in both MCF-7 and MDA-MB-231 cells. Compared to the 
control, the expression of Bcl-xl significantly decreased by As2S2 at 16 µM in both cell lines (P = 
0.0014 in MCF-7 and P = 0.0015 in MDA-MB-231). 
Taken together, these results indicate that As2S2 induced apoptosis in both MCF-7 and 
MDA-MB-231 cells in a dose-dependent manner by regulating apoptosis-related proteins. 
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Figure 2-8  As2S2 induces apoptosis in breast cancer cells. (A) MCF-7 and (B) MDA-MB-231 
cells were treated with 0, 4, 8, and 16 µM As2S2 for 48 h, followed by staining with Annexin V/PI, 
and then analyzed by flow cytometry. The cells were assessed for the total number of apoptotic 
cells, including early apoptotic (Annexin V+/PI-) and late apoptotic (Annexin V+/PI+) cells. Data 
are expressed as the mean ± SEM (n ≥ 3). Asterisks indicate significant differences between 
the control (As2S2 0 µM) and the As2S2-treated groups (*P < 0.05, **P < 0.01).  
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Figure 2-9  Effects of As2S2 on the caspase protein expression in breast cancer cells. MCF-7 
and MDA-MB-231 cells were treated with 0, 4, 8, and 16 µM As2S2 for 48 h. Western blot assays 
were carried out to examine the effects of As2S2 on the expression of caspase-7 and caspase-8 in 
both cell lines after 48 h of treatment. β-actin was used as an internal control. All images are 
representative of three independent analyses from three independent cellular preparations. 
Asterisks indicate significant differences between the control (As2S2 0 µM) and the As2S2-treated 
groups (*P < 0.05, **P < 0.01). 
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Figure 2-10  Effects of As2S2 on the expression of Bcl-2 protein family in breast cancer cells.  
MCF-7 and MDA-MB-231 cells were treated with 0, 4, 8, and 16 µM As2S2 for 48 h. Western blot 
assays were carried out to examine the effects of As2S2 on the expression of Bax, Bcl-2 and Bcl-xl 
in both cell lines after 48 h of treatment. β-actin was used as an internal control. All images are 
representative of three independent analyses from three independent cellular preparations. 
Asterisks indicate significant differences between the control (As2S2 0 µM) and the As2S2-treated 
groups (*P < 0.05, **P < 0.01). 
 
3.5  As2S2 induces autophagy in breast cancer cells. 
When autophagy is induced, microtubule-associated protein 1 light chain 3 (LC3) is converted 
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from the cytoplasmic form LC3-I to the membrane-associated form LC3-II. The ratio of 
LC3-II/LC3-I is widely regarded as a primary marker of autophagy activation [104, 105]. 
As shown in Figure 2-11, As2S2 induced an increase in the LC3-II/LC3-I ratio in both MCF-7 
and MDA-MB-231 cells. Compared to the control, significant increases were observed in MCF-7 
cells after treatment with As2S2 at 8 µM (P = 0.0007) and 16 µM (P = 0.0187). Similarly, the ratio 
of LC3-II/LC3-I was markedly elevated in MDA-MB-231 cells after treatment with As2S2 at 8 µM 
(P = 0.0048) and 16 µM (P = 0.0358).  
 
 
Figure 2-11  Effects of As2S2 on the expression of autophagy hallmarks in breast cancer 
cells.  MCF-7 cells were treated with 0, 4, 8, and 16 µM As2S2 for 48 h, and Western blot assays 
were carried out to examine the expressions of autophagy markers LC3-I and LC3-II in both cell 
lines. The ratio of LC3-II to LC3-I was calculated to determine the autophagic level. β-actin was 
used as an internal control. All images are representative of three independent analyses from three 
independent cellular preparations. Asterisks indicate significant differences between the control 
(As2S2 0 µM) and the As2S2-treated groups (*P < 0.05, **P < 0.01). 
 
Autophagy has been shown to play roles in both cytoprotective and cytotoxic processes. To 
examine the effect of As2S2-induced autophagy on breast cancer cell growth, both MCF-7 and 
MDA-MB-231 cells were exposed to the autophagy inhibitor chloroquine diphosphate salt (CQ) in 
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the presence of different concentrations (0, 4, 8, and 16 µM) of As2S2. As shown in Figure 2-12A, 
CQ did not alter the inhibitory effect of As2S2 on MCF-7 cell viability. Furthermore, while CQ 
significantly reversed the cell death induced by 4 µM As2S2 (P = 0.0021) in MDA-MB-231 cells, 
no extra effect of CQ on the cytotoxicity of 8 or 16 µM As2S2 (Figure 2-12B) was observed. 
 
 
Figure 2-12  Cell viability in breast cancer cells following autophagy inhibition and As2S2 
treatment. (A) MCF-7 and (B) MDA-MB-231 cells were pretreated with 10 µM of autophagy 
inhibitor CQ for 1 h before treatment with 0, 4, 8, and 16 µM As2S2 for 48 h. Cell viability was 
determined by CCK-8 assays. Data are presented as the mean ± SEM (n ≥ 3). **P < 0.01 vs. 
respective controls (As2S2 0 µM or CQ 0 µM); ##P < 0.01 vs. respective As2S2 treatment groups in 
the absence of CQ.  
 
3.6  Effects of As2S2 on the ROS production in breast cancer cells.  
The effects of As2S2 on the ROS production in breast cancer cells were assessed using a 
ROS-sensitive probe, DCF-DA, and flow cytometry.  
As shown in Figure 2-13, As2S2 induced accumulation of ROS in a dose-dependent manner in 
both breast cancer cell lines. The percentages of ROS production in MCF-7 cells significantly 
increased from 23.7 ± 1.8 % in the control to 29.6 ± 1.2 % (P = 0.0353) and 33.3 ± 0.3 % (P = 
0.0022) by 8 and 16 µM As2S2, respectively. In MDA-MB-231 cells, 4, 8, and 16 µM As2S2 
significantly increased the percentages of ROS production from 6.8 ± 0.1 % in the control to 22.3 
± 1.7 % (P = 0.0001), 27.1 ± 1.2 % (P < 0.0001) and 28.3 ± 1.4 % (P < 0.0001), respectively.  
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Figure 2-13  Effects of As2S2 on the ROS production in breast cancer cells.  MCF-7 and 
MDA-MB-231 cells were treated with 0, 4, 8, and 16 µM As2S2 for 48 h. Intracellular ROS levels 
were analyzed using the ROS-responsive dye DCF-DA followed by flow cytometry. Data are 
presented as the mean ± SEM (n ≥ 3). *P < 0.05, **P < 0.01 vs. control (As2S2 0 µM).  
 
3.7  Effects of As2S2 on cell survival-related proteins in breast cancer cells. 
To further investigate the molecular mechanism underlying the inhibitory effects of As2S2 on 
cell survival and growth in breast cancer cells, we evaluated the effect of As2S2 on pro-survival 
PI3K/Akt pathway. Abundant evidences demonstrate the essential role of this cell survival 
pathway in cell growth, proliferation, and survival [106, 107]. The protein expressions of PI3K 
and Akt were detected in breast cancer cells by western blot analysis. 
As shown in Figure 2-14, in both MCF-7 and MDA-MB-231 cells, the protein expressions of 
PI3K and Akt were effectively down-regulated by As2S2 in a dose-dependent manner. Compared 
to control, the expression levels of PI3K in MCF-7 and MDA-MB-231 cells significantly 
decreased by As2S2 treatment (P < 0.05). Moreover, significant decreases of Akt expression were 
observed in both cells after treatment with 16 µM of As2S2 (P = 0.0006 in MCF-7 and P = 0.0181 
in MDA-MB-231).  
Collectively, the results suggest that the blockade of PI3K/Akt signals by As2S2 in breast 
cancer cells contribute to the induction of apoptosis as well as the inhibition of cell viability 
following As2S2 exposure. 
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Figure 2-14  Effects of As2S2 on the expression of cell survival related-proteins.  MCF-7 and 
MDA-MB-231 cells were treated with 0, 4, 8 and 16 µM As2S2 for 48 h, and Western blot assays 
were carried out to examine expression of PI3K and Akt. β-actin was used as an internal control. 
All images are representative of three independent analyses from three independent cellular 
preparations. Asterisks indicate significant differences between the control (As2S2 0 µM) and the 
As2S2-treated groups (*P < 0.05, **P < 0.01).  
 
4. DISCUSSION 
Previous studies have reported antitumor effects of As2S2 against hematopoietic and solid 
cancer cell lines [34, 43, 95], but few have explored the As2S2 effects on breast cancer cells. In the 
present study, I investigated the anticancer effects of As2S2 on the proliferation and migration of 
two distinctive subtypes of breast carcinoma MCF-7 and MDA-MB-231 cells, and explored the 
underlying mechanisms particularly with regard to the activation of programmed cell death, which 
includes apoptosis and autophagy. Tumor metastasis is a multistep aggressive process involving 
cell proliferation and cell migration [108, 109]. In this section, the effects of As2S2 on cell survival 
and migration were also investigated.  
As2S2 significantly inhibited the cell viabilities in both cell lines in a dose-dependent manner 
(Figure 2-1). Consistent with these findings, the data visualized and measured via the calcein AM 
staining test showed the potent induction of cell death by As2S2 in both cell lines (Figure 2-2 and 
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Figure 2-3). In addition, the results from wound healing assays showed a significant decrease in 
the cell invasion by treatment with As2S2 in a dose-dependent manner in both cell lines (Figure 
2-4), which further suggested tumor suppressor effects of As2S2 by repressing  proliferative and 
migratory abilities of breast carcinoma cells. MMPs are closely associated with extracellular 
matrix degradation, which leads to cancer cell invasion and metastasis. MMP-9 is a key factor that 
contributes to the metastatic potential and cancer progression [110]. Migration and invasion of 
cancer cells are facilitated by MMP-9. Thus, down-regulation of MMP-9 is a possible strategy for 
attenuating the progression of cancer cells [111]. My present results showed that As2S2 reduced 
the protein expression of MMP-9 in both breast cancer cell lines in a dose-dependent manner, 
which may account for the reduction in metastasis in both cell lines after As2S2 treatment.  
Cell cycle dysfunction is a common feature of proliferating and metastatic breast tumor cells 
[112], and therefore, targeting cell cycle regulation is an important therapeutic strategy. In this 
study, As2S2 treatment exerted pronounced cell cycle arrest at G2/M phase in both breast cancer 
cell lines in a dose-dependent manner (Figure 2-6). In addition, As2S2 triggered G0/G1-phase 
arrest in MCF-7 cells and S-phase arrest in MDA-MB-231 cells (Figure 2-6). The exertion of cell 
arrest at different phases between the two cell lines is most likely due to characteristics specific to 
these cells as distinct subtypes of breast carcinoma. Given the observed cell cycle arrests, the 
present results suggest that As2S2 regulates the expression of cell cycle-related proteins involved 
in the corresponding phases of cell cycle in each of the breast cancer cell lines (Figure 2-7). For 
example, as the main regulatory proteins in the G2/M phase [113, 114], the expression of cyclin 
B1 and cdc2 was regulated by As2S2 treatment in both cell lines, which is in agreement with the 
blockage of cell cycle at G2/M by As2S2 exposure. Intriguingly, the protein expression of cyclin 
B1 was regulated by As2S2 in an opposite manner between MCF-7 and MDA-MB-231 cells, 
possibly due to biological variations and distinctions between these two cell lines. In addition, 
cdc2 has also been described as a key regulator tightly related to G0/G1 and S phases [115], which 
accounts for the cell cycle arrest at G0/G1 phase in MCF-7 cells and at S phase in MDA-MB-231 
cells. 
Apoptosis and autophagy are two well-known mechanisms of programmed cell death that play 
essential roles in maintaining organismal and cellular homeostasis [116]. Apoptosis, regarded as a 
major mechanism of chemotherapy-induced cell death [117], is characterized by typical 
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morphological changes, such as nuclear condensation and fragmentation. In this section, apoptosis 
was significantly induced by As2S2 treatment in both breast cancer cell lines, as demonstrated by 
the Annexin V staining assay and Hoechst 33342 staining assay. In addition, the induction of 
apoptosis in both breast cancer cell lines was further confirmed by the activation of caspase-8 and 
caspase-7 (Figure 2-9) as well as the regulation of proteins in the Bcl-2 family (Figure 2-10), 
which resulted in an increase in the Bax/Bcl-2 ratio along with the decreased expression of Bcl-xl. 
An essential step in triggering apoptosis is the activation of caspases, a family of cysteine 
proteases that are ubiquitously expressed as death proteases [72]. The caspase family has 
traditionally been divided into initiator and effector caspases. Activated initiator caspases, such as 
caspase-8, caspase-9 and caspase-10, subsequently initiate a caspase cascade of downstream 
effector caspases [73]. Effector caspases, such as caspase-3, caspase-6 and caspase-7, are 
understood to execute apoptosis after they are triggered by initiator caspases [73]. Two main 
signal pathways exist to induce cell apoptosis: the extrinsic cell death receptor pathway and the 
intrinsic mitochondrial pathway [118]. Of note, caspase-8 has been regarded as a core initiating 
component of the extrinsic pathway, which subsequently activates the execution phase of 
apoptosis (e.g., activating effector caspase-7) [119]. Bcl-2 family proteins are categorized into 
subgroups based on their pro- or anti-apoptotic actions, giving pro-apoptotic proteins such as Bax, 
and anti-apoptotic proteins such as Bcl-2 and Bcl-xl. These Bcl-2 family proteins play an 
important role in initiating the intrinsic apoptotic pathway [120, 121]. In this section, the 
expression of caspase-8 and the Bax/Bcl-2 ratio significantly increased, while the expression of 
Bcl-xl markedly decreased after As2S2 exposure, suggesting that both the extrinsic and intrinsic 
pathways were involved in As2S2-induced apoptosis in both breast cancer cell lines. 
Apoptosis and autophagy normally occur in the same cell, mostly in a mutually interactive 
manner under the same cellular conditions [116]. Autophagy, a catabolic process for the 
degradation of unnecessary and dysfunctional cytosolic components and organelles, has generally 
been regarded as the type II (non-apoptotic) programmed cell death, and is deemed as an 
important mechanism involved in the tumor control process [122, 123]. LC3 is a key protein 
involved in initiating autophagy, wherein LC3-I is lipidated and converted to LC3-II. The ratio of 
LC3-II/LC3-I is widely used as a primary marker of autophagy activation [105]. As2S2 treatment 
induced an increase in the ratio of LC3-II/LC3-I in both breast cancer cell lines, indicating that 
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autophagy occurs in breast cancer cells following exposure to As2S2. Bcl-2 is an intermediary 
protein shared by both apoptosis and autophagy, and is known to play an anti-apoptotic and 
anti-autophagy role in both processes [124]. The present results provided evidence that As2S2 
treatment significantly decreased the Bcl-2 protein expression, which may in turn potentiate the 
induction of autophagy. Intriguingly, autophagy is commonly regarded as a double-edged sword 
[125, 126] and may positively or negatively influence cancer cell growth [127]. To better 
understand the role of autophagy in this study, we used CQ, a pharmacological inhibitor of 
autophagy, to clarify whether or not As2S2-induced cell death was related to the induction of 
autophagy. The results showed that CQ significantly reversed the inhibitory effect of 4 µM As2S2 
on the cell viability in MDA-MB-231 cells, indicating that autophagy induced by As2S2 at a 
relatively low concentration was indeed involved in the death of MDA-MB-231 cells. In contrast, 
CQ had little effect on the death of MCF-7 and MDA-MB-231 cells in the presence of relatively 
high concentrations (8 and 16 µM) of As2S2. These observations suggest that the As2S2 induced 
cell death is primarily through apoptosis and cell cycle arrest rather than autophagy. 
ROS regulate a series of biological processes, including programmed cell death [128]. It has 
been reported that the accumulation of ROS is closely associated with cell apoptosis, cell cycle 
arrest and autophagy induced by anticancer agents, which consequently leads to negative effects 
on the cell survival, proliferation and metastasis [129-132]. In particular, ROS can activate and 
modulate apoptosis when cells are under stress. ROS levels increase in cells exposed to various 
stress agents, including anticancer drugs. In addition, ROS can act directly on the apoptotic 
machinery, by accelerating mitochondrial depolarization and dysfunction during the effector phase 
of apoptosis [133]. The present data from flow cytometry analyses indicated that the ROS level in 
both MCF-7 and MDA-MB-231 cells significantly increased by As2S2 treatment dose-dependently 
(Figure 2-13), which may potentiate the induction of apoptosis, cell cycle arrest and autophagy. 
Accordingly, it is suggested that the oxidative stress generated by ROS may remarkably decrease 
cell viability, live cell number, and cell growth in both MCF-7 and MDA-MB-231 cells.  
In addition, PI3K/Akt signaling pathway implicates in tumorigenesis by regulating cell growth, 
cell cycle progression, cell apoptosis, and cell metabolism [106, 107]. Disruption of PI3K/Akt 
signals attenuates cell survival, restrains tumor growth, and promotes pro-apoptotic activities 
[134]. As2S2 treatments suppressed the PI3K/Akt signals in the two breast cancer cell lines with 
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similar dose-dependent manner. These observations suggest the possible inhibitory function of 
As2S2 to control cancer cell survival signals, which acts in accordance with the regulation of 
apoptotic signals as well as cell cycle related proteins. 
The data of this section thus identified the antitumor effects of As2S2 against breast carcinoma 
in vitro, which includes inhibition of cell proliferation, cell survival and invasion of MCF-7 and 
MDA-MB-231 cells. These effects of As2S2 were associated with blockade of cell cycle 
progression, as well as induction of apoptosis and autophagy. Decrease in MMP-9 expression, 
inhibition of PI3K/Akt signals, and cellular ROS accumulation are suggested to be implicated in 
the underlying mechanisms of action of As2S2.  
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CHAPTER THREE 
Synergistic antitumor effects of arsenic disulfide in combination with buthionine sulfoximine 
on breast cancer cells 
 
1. INTRODUCTION 
My data shown in Chapter one revealed that 3D cultured MCF-7 cells exhibit resistance to the 
suppressive effects of As2S2, which may reflect the native tumor characteristics in vivo [135-137]. 
In addition, As2S2 still has disadvantages related to its toxicity as an anticancer drug and poor 
solubility that almost insoluble in water [15, 138]. Thus, new therapeutic strategies and 
approaches are urgently required to increase the anticancer efficacy and decrease the dosage of 
As2S2.  
Combination chemotherapy represents an effective approach to potentiate the therapeutic 
efficacy, overcome drug resistance, reduce adverse effects and minimize drug dosage of each 
compound alone [139, 140]. Indeed, arsenic compounds including As2S2 have been reported to 
exhibit an enhanced antitumor potential in combined with other chemotherapeutic drugs [141-143], 
and such combination consequently maximizes therapeutic efficacies and minimizes toxicities of 
arsenics. One candidate that can synergize the anticancer activity of arsenic compounds is 
L-buthionine-(S, R)-sulfoximine (BSO), a GSH biosynthesis inhibitor [144]. GSH is known to be 
essential for cancer cell proliferation, disease progression, and drug resistance [145-147]. 
Combination of ATO and BSO has been reported to exert potent synergistic anticancer effects 
against leukemia and solid cancer cells [148, 149]. Since As2S2 is an arsenic compound with 
similar anticancer effects as arsenic trioxide but with much less toxicity, it is intriguing to evaluate 
the synergistic potential of As2S2 in combination with BSO against cancer cells, which has been 
rarely reported before.  
The aim of this Chapter is to investigate the synergistic anticancer effects of As2S2 combined 
with BSO on human breast cancer MCF-7 cells cultured in both 2D monolayers and 3D spheroids, 
and in particular, to gain insights into the underlying mechanisms that might be involved. 
 
2. MATERIALS AND METHODS 
2.1  Reagents  
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As2S2, PI solution, RNase A, calcein-AM, Hoechst 33342, CCK-8 assay kit, FITC Annexin V 
Apoptosis Detection Kit, ECLTM Western Blotting Analysis System, ECLTM Prime Western 
Blotting Detection Reagent, mouse anti-human cyclin B1, caspase-8, rabbit anti-human caspase-7, 
Bcl-2, Cdc2, PI3K and Akt were obtained from the same manufactures mentioned in the Chapter 
two (Materials and Methods, 2.1) and Chapter one (Materials and Methods in Section one, 2.1). 
BSO was purchased from Sigma (St. Louis, MO, USA). Rabbit anti-human Myeloid cell leukemia 
1 (Mcl-1), cyclin D1, mouse anti-human cyclin A2, and cellular glutathione detection assay kit 
were obtained from Cell Signaling (Danvers, MA, USA).  
 
2.2  Cell line and cell culture 
The information of human breast cancer cell line MCF-7 and cell culture in both 2D and 3D 
conditions was applied in the same way as mentioned in the Section one of Chapter one (Materials 
and Methods, 2.2).  
 
2.3  2D- and 3D-cell culture assay 
The information of 2D- and 3D-cell culture assays was applied in the same way as mentioned 
in Section one of Chapter one (Materials and Methods, 2.3 and 2.4). Stock solution of 0.1 mg/ml 
BSO was prepared by dissolving BSO in distilled H2O. For the pretreatment with BSO, 1 μM of 
BSO was added to the cells 1 h before administration of As2S2. 0.6 mM As2S2 solution was 
prepared as described in the Section one of Chapter one (Materials and Methods, 2.6). After 
treatment with 1 μM BSO or/and 4 μM As2S2 for 72 h, 4 × 105 MCF-7 cells were collected and 
used for subsequent experiments including apoptosis detection, cell cycle assay, GSH assessment 
and Western blotting. MCF-7 cells cultured with MEM-alpha medium in the absence of drug were 
used as a control.  
 
2.4  Cytotoxicity assay  
Cell cytotoxicity was analyzed by using CCK-8 assay with the same operations mentioned in 
the Section one of Chapter one (Materials and Methods, 2.6).  
 
2.5  Microscopy images 
65 
 
MCF-7 cells were seeded in 2D- and 3D-cultured 48-well plates at a density of 1 × 104 
cells/well, followed by exposure to 0 or 4 µM As2S2, with or without pretreatment by BSO, for 72 
h, respectively. The morphological structures of MCF-7 cells in 2D‑ and 3D‑cultures after 72 h 
drug treatment were observed by using an IX70® inverted microscope (Olympus Corporation, 
Tokyo, Japan). Series of bright‑field images were recorded with 10× and 20× objectives (original 
magnifications: ×100 and ×200 respectively).  
Moreover, MCF-7 cells were seeded in 2D black 96-well plates with a clear bottom 
(CellCarrierTM-96, PerkinElmer, Massachusetts, USA) and 3D spheroid 96-well plates 
(CellCarrierTM-96, PerkinElmer, Massachusetts, USA) at a density of 5 × 103 cells/well, followed 
by exposure to 0 or 4 µM As2S2, with or without pretreatment by BSO, for 72 h, respectively. 
Then the cells were stained for 30 min in the dark at 37°C with calcein-AM, Hoechst 33342 and 
PI solutions followed by image measurement and analyses by a fluorescence micro-plate reader 
and Harmony software (Operetta CLS, PerkinElmer, Japan).     
 
2.6  Assessment of apoptosis 
Apoptotic cells were detected by using FITC Annexin V Apoptosis Detection Kit. The staining 
procedure was performed according to the manufacturer’s instructions. Approximately 1×104 cells 
were analyzed by using a flow cytometer (BD Biosciences, CA, US). The cells were subsequently 
assessed for total apoptotic index which is derived from total apoptotic cells composed by early 
apoptotic (Annexin V+/PI-) and late apoptotic (Annexin V+/PI+) cells. 
 
2.7  Cell cycle analysis 
After the culture, the cells were harvested and washed with PBS. Subsequently, the cells were 
fixed in 70% ethanol overnight at -20°C, and stained with PI and RNase A solution (5 μg/ml PI, 
and 0.5 μg/μl RNase A). The DNA content was determined by flow cytometry (BD Biosciences, 
CA, US), and the data were analyzed by CellQuest analysis software. ModFit LT™ Ver.3.0 (Verity 
Software House, Topsham, ME, USA) was used to calculate the number of cells at each G0 /G1, S 
and G2/M phase fraction. 
 
2.8  Western blot analysis  
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Western blot was performed to evaluate the protein levels of caspase-7, caspase-8, Bcl-2, 
Mcl-1, cyclin A2, cyclin B1, cyclin D1, Cdc2, PI3K and Akt in 2D- and 3D-cultured MCF-7 cells. 
The total protein was extracted from MCF-7 cells treated with 4 µM of As2S2, with or without 
pretreatment by BSO, for 72 h. The procedures and operations of Western blot is the same with 
that described in the Section one of Chapter one (Materials and Methods, 2.8).  
 
2.9  Measurement of GSH 
GSH levels of MCF-7 cells in both 2D- and 3D-cultured systems were measured using a 
cellular glutathione detection assay kit (Cell Signaling, 13859) according to the manufacturer’s 
instructions. Following treatment by As2S2 with or without BSO, MCF-7 cells were collected and 
treated by the Digitonin Lysis Buffer for 5 min on ice, then followed by centrifugation at 14,000 
rpm for 10 min. Supernatants were collected, mixed with Tris Assay Buffer and Working Solution, 
and then incubated in a black 96-well plate with clear bottom (CellCarrierTM-96, PerkinElmer, 
Massachusetts, USA) at room temperature for 60 min. Read plate with a micro-plate reader 
(Corona MT P-32; Corona Co., Hitachi, Ibaraki, Japan) at an excitation wavelength of 380 nm and 
emission wavelength of 485 nm.  
 
2.10  Statistical analysis 
Statistical analyses were performed using software GraphPad Prism version 6.0 for Windows 
(San Diego, CA). Statistically significant differences for multiple comparisons were determined 
by one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test. Data were 
presented as means ± SEM of at least three independent experiments. P < 0.05 was considered to 
be statistically significant.  
 
3. RESULTS 
 
3.1 BSO enhances the cytotoxic effect of As2S2 in 2D- and 3D-cultured MCF-7 cells 
MCF-7 cell viabilities in both 2D- and 3D-cultured systems were determined by CCK-8 assay 
after exposure to 0-16 µM As2S2 and 1 µM BSO, either alone or in combination, for 72 h.  
As shown in Figure 3-1A and Figure 3-1B, MCF-7 cells cultured in spheroids exhibited 
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resistance to the suppressive effects of relatively low concentrations of As2S2, when compared to 
those cultured in monolayers. The mean IC50 value of As2S2 on MCF-7 spheroids was 
approximately 2.2 times higher than that on the MCF-7 monolayers (Figure 3-1D). In BSO (1 µM) 
alone did not show any cytotoxic effect on both MCF-7 monolayers and spheroids (Figure 3-1A 
and 3-1B).  
As2S2 in combination with BSO exhibited significantly enhanced inhibitory effects on cell 
viabilities of both MCF-7 monolayers and spheroids compared with As2S2 alone (Figure 3-1A-C). 
The mean (SEM) IC50 values of As2S2 alone were 5.2 ± 0.6 and 11.6 ± 1.9 µM in 2D- and 
3D-cultured MCF-7 cells, respectively. When combined with BSO, the mean (SEM) IC50 values 
of As2S2 were 2.3 ± 0.1 and 1.5 ± 0.5 µM in monolayers and spheroids, respectively, which were 
significantly lower than the IC50 values of As2S2 alone (P < 0.01) (Figure 3-1D).  
Then, we introduced the combination index (CI) from Chou-Talalay median-effect method 
[150] to define the synergistic effects of BSO in addition to As2S2. According to the Chou-Talalay 
median-effect method, the combined treatment is considered to be synergism (CI < 1), antagonism 
(CI > 1) or additive (CI = 1) effect, respectively. As shown in Table 3-1 and 3-2, all of the CI 
values of As2S2 (from 2 to 16 µM) combined with BSO (1 µM) were less than 1, indicating that 
the combination of As2S2 and BSO is synergistic in both 2D- and 3D-cultured MCF-7 cells.  
Bright-field microscopic and fluorescent dye staining images further confirmed the synergistic 
inhibitory effect of As2S2 with BSO on both MCF-7 monolayers and spheroids. As shown in 
Figure 3-2, the exposure to the combination of As2S2 and BSO caused much more substantial 
morphological defects in both the 2D- and 3D-cultured MCF-7 cells compared to the exposure to 
each drug alone. As shown in Figure 3-3, As2S2 combined with BSO exerted an enhanced decrease 
of live cells which were labeled by Calcein-AM probes with green fluorescence. Whereas, the 
combined treatment further augmented increase in number of dead cells that marked by PI probes 
with brown fluorescence, in both 2D-monolayers and 3D-spheroids. 
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Figure 3-1  BSO augments As2S2-indued cell death in both 2D- and 3D-cultured MCF-7 
cells.  MCF-7 cells in two culture systems were treated with the combination of As2S2 and BSO 
or each agent alone at the indicated concentrations for 72 h. Cell viability was detected by CCK-8 
assays. Percentages of cell viabilities in (A) MCF-7 monolayers and (B) MCF-7 spheroids 
following exposure to different concentrations of As2S2 (0-16 µM), 1 µM of BSO or both for 72 h 
were shown. (C) Dose‑response curves for the inhibitory effects of As2S2 alone (〇 for 2D and 
△ for 3D) or combined with 1 µM BSO (● for 2D and ▲ for 3D) on cell viability of MCF-7 
cells. (D) The mean IC50 values of As2S2 alone or As2S2 combined with BSO on cell viabilities of 
MCF-7 monolayers (2D) and spheroids (3D). Data were presented as mean ± SEM (n ≥ 3). **P < 
0.01 vs. 2D, ##P < 0.01 vs. As2S2 alone.  
 
Table 3-1 Combination index (CI) of As2S2 and buthionine sulfoximine (BSO) for inhibiting 
proliferation of 2D cultured MCF-7 cells. 
As2S2  
(µM) 
BSO 
(µM) 
MCF-7 (2D) 
Fa ± SEM CI ± SEM Description 
2 1 0.45 ± 0.01 0.63 ± 0.07 Synergism 
4 1 0.72 ± 0.01 0.34 ± 0.05 Synergism 
8 1 0.94 ± 0.00 0.10 ± 0.02 Synergism 
12 1 0.97 ± 0.01 0.06 ± 0.01 Synergism 
16 1 0.98 ± 0.00 0.05 ± 0.02 Synergism 
CI: combination index  
Fa values represent the growth inhibition ratio to a given drug combination. 
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CI values represent the assessment of synergism induced by drug combination.  
CI values were <1, =1, and >1 indicating synergism, additive, and antagonism, respectively.  
Experiments were performed at least three times, and data were presented as mean ± SEM. 
 
Table 3-2 Combination index (CI) of As2S2 and buthionine sulfoximine (BSO) for inhibiting 
proliferation of 3D cultured MCF-7 cells. 
As2S2  
(µM) 
BSO 
(µM) 
MCF-7 (3D) 
Fa ± SEM CI ± SEM Description 
2 1 0.63 ± 0.08 0.08 ± 0.03 Synergism 
4 1 0.70 ± 0.11 0.12 ± 0.06 Synergism 
8 1 0.94 ± 0.01 0.02 ± 0.01 Synergism 
12 1 0.94 ± 0.01 0.03 ± 0.01 Synergism 
16 1 0.96 ± 0.01 0.02 ± 0.01 Synergism 
CI: combination index  
Fa values represent the growth inhibition ratio to a given drug combination. 
CI values represent the assessment of synergism induced by drug combination.  
CI values were <1, =1, and >1 indicating synergism, additive, and antagonism, respectively.  
Experiments were performed at least three times, and data were presented as the mean ± SEM. 
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Figure 3-2  Changes in morphology of MCF-7 monolayers and spheroids induced by As2S2 
and BSO.  MCF-7 cells were seeded at a density of 10,000 cells per well, followed by treatment 
by 4 µM As2S2, 1 µM BSO, and their combination in 2D (left two columns) and 3D (right two 
columns) cultured systems for 72 h. Bright-field images of MCF-7 cells were acquired using an 1 
x 70 inverted microscope (Olympus Corporation, Tokyo, Japan), with 10× and 20× objectives 
(original magnifications 100× and 200×, respectively). Scale bar represents 1 mm. BSO: 
buthionine sulfoximine.  
 
 
Figure 3-3 Changes in Calcein-AM, Hoechst 33342, and PI stained mrphology induced by 
As2S2 and BSO in 2D- and 3D-cultured MCF-7 cells. Both MCF-7 monolayers (2D) and 
spheroids (3D were seeded at a density of 5,000 cells per well, followed by treatment with 4 µM 
As2S2, 1 µM BSO, and the combination for 72 h. Viable cells exposed to Calcein-AM (first line) 
showed bright green fluorescence. Hoechst staining (second line) as nuclear counterstain showed 
bright blue fluorescence. Dead cells exposed to PI (third line) showed bright brown fluorescence. 
Merging (fourth line) of Calcein-AM, Hoechst and PI showed blending fluorescence. Images were 
taken and analyzed by a fluorescence Micro-plate reader (Operetta CLS, PerkinElmer, Japan) with 
10× objective for 2D condition (original magnifications 100×) and 5× objective for 3D condition 
(original magnifications 50×). BSO: buthionine sulfoximine.  
 
3.2 BSO enhances As2S2 triggered cell cycle arrest in 2D- and 3D-cultured MCF-7 cells  
To investigate the cytotoxic mechanism underlying the synergistic inhibition in cell viability 
with As2S2 and BSO combination, we conducted cell cycle analysis in 2D- and 3D-cultured 
MCF-7 cells. 
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Figure 3-4 BSO augments cell cycle arrest triggered by As2S2 in both 2D- and 3D-cultured 
MCF-7 cells. MCF-7 cells cultured in (A) 2D and (B) 3D systems were treated with 4 µM of 
As2S2 and 1 µM of BSO, alone or in combination, for 72 h. The peaks in the histograms represent 
the G0/G1, S, and G2/M phases in cell cycle, respectively. Percentages of cell numbers in each 
phase were assessed (lower two figures). All data were expressed as mean ± SEM (n ≥ 3). *P < 
0.05, **P < 0.01 vs. control; ##P < 0.01 vs. As2S2 alone.  
 
As shown in Figure 3-4A, in MCF-7 monolayers, combined treatment with As2S2 and BSO 
significantly increased the percentage of cells arrested at S phase of cell cycle (20.7 ± 3.8 %) 
compared to control (11.9 ± 0.4 %; P = 0.0482). Similarly, in spheroids (Figure 3-4B), the 
combination of As2S2 and BSO significantly increased the percentage of cells arrested at S phase 
(34.1 ± 1.0 % vs. 15.4 ± 1.0 % in control; P < 0.0001) while it markedly reduced the percentage of 
cells at G0/G1 phase, as compared to control (45.0 ± 0.8 % vs. 66.0 ± 0.7% in control; P < 
0.0001). Importantly, there were significant differences in both the increased S phase-cell 
percentages (P < 0.0001) and the decreased G0/G1 phase-cell percentages (P < 0.0001), 
respectively, between the cells treated with the combined therapy and those treated with As2S2 
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alone, in 3D-cultured MCF-7 cells. 
Subsequently, we examined the expression of cell cycle-related proteins by western blotting. 
As shown in Figure 3-5A-E, As2S2 and BSO combination in MCF-7 monolayers (2D) 
significantly inhibited the expression amounts of cyclin A (P < 0.0001) (Figure 3-5B), cyclin B (P 
= 0.0031) (Figure 3-5C), cyclin D (P = 0.0003) (Figure 3-5D) and cdc2 (P = 0.0036) (Figure 
3-5E), respectively. Treatment of cells with As2S2 and BSO in combination significantly enhanced 
the inhibitory effects of As2S2 alone on the expression amounts of cyclin A, cyclin D and cdc2 (P 
< 0.01). Similarly, in 3D spheroids (Figure 3-5F-J), As2S2 combined with BSO significantly 
decreased the expression amounts of all of these cell cycle-related proteins compared to control (P 
< 0.05).  
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Figure 3-5  Effects of As2S2 alone or in combination with BSO on expression of cell cycle 
related proteins in 2D- and 3D-cultured MCF-7 cells.  Western blot assays were carried out to 
examine the effects of As2S2 and BSO, alone or in combination, in 2D (A-E) and 3D (F-J) culture 
systems on expressions of key proteins cyclin A (B and G), cyclin B (C and H), cyclin D (D and 
I) , and Cdc2 (E and J) in cell cycle of MCF-7 cells. Protein β-actin was used as internal control. 
All images in A and F are representative of three independent analyses.  Bars in B-E and G-J 
indicate means ± SEM (n = 3) of the expression ratio obtained from three independent cellular 
preparations. Asterisks (*) indicate significant differences between the control and the drug 
treatment groups (*P < 0.05, **P < 0.01); Hashes (#) indicate significant differences between the 
combination and As2S2 alone (#P < 0.05, ##P < 0.01).  
 
3.3  BSO augments As2S2 induced apoptosis in 2D- and 3D-cultured MCF-7 cells 
To investigate whether the observed synergism is associated to apoptosis induction, Annexin 
V/PI double staining assay, followed by flow cytometry analysis, was performed in 2D- and 
3D-cultured MCF-7 cells. As shown in Figure 3-6, after 72 h treatment, little induction of 
apoptosis was observed in both MCF-7 monolayers and spheroids treated with either 4 µM As2S2 
or 1µM BSO mono-treatment. In contrast, As2S2 combined with BSO resulted in up to 9.4 ± 1.4 
folds raise of apoptosis indices in monolayers (P = 0.0004), and 1.8 ± 0.3 folds raise in spheroids 
(P = 0.0477), respectively.  
We next investigate the influence of As2S2 and BSO alone or in combination on cell 
morphological structure by staining the cells with Hoechst 33342 in both MCF-7 monolayers and 
spheroids (Figure 3-3). Cell shrinkage, nuclear condensation and fragmentation appeared in 
MCF-7 monolayers after combined treatment with As2S2 and BSO, whereas untreated cells 
displayed round shapes and homogeneous staining. In MCF-7 spheroids, the combined treatment 
with As2S2 and BSO resulted in distortion of cell skeleton in spheroids. In contrast, the untreated 
cells and the cells treated with either of 4 µM As2S2 or 1 µM BSO alone showed normal shapes 
and relatively clear skeletons.  
These observations were further confirmed by the analysis of proteins involved in apoptosis 
induction. In MCF-7 monolayers, there were significant increases in expression amounts of 
apoptosis marker caspase-7 in cells underwent the combination treatment (P = 0.0002), as 
compared to cells treated by either of As2S2 or BSO alone (Figure 3-7A and 3-7B). Significantly 
high levels of activated caspase-8 were also observed in cells treated by combination of As2S2 and 
BSO (P = 0.0483) (Figure 3-7A and 3-7C), indicating that the combined treatment induced 
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caspase-dependent apoptosis in 2D-cultured MCF-7 cells. In contrast, the combination treatment 
caused significant decrease of caspase-7 (P = 0.0008) as well as a reduced trend of caspase-8 in 
3D-cultured MCF-7 cells (Figure 3-7D-F).  
In addition, significant decrease in amounts of Bcl-2 (P = 0.0428) and Mcl-1 (P = 0.0140) 
were observed in MCF-7 spheroids following the combined treatment with As2S2 and BSO, while 
each agent alone showed no significant effect on the expression amounts of these proteins (Figure 
3-8D-F). In monolayers (Figure 3-8A-C), significant inhibition of the expression amounts of these 
anti-apoptotic proteins was observed after the combination treatment (P < 0.01), as well as As2S2 
mono-treatment (P < 0.05). 
 
 
Figure 3-6  BSO augments apoptosis induced by As2S2 in both 2D- and 3D-cultured MCF-7 
cells.  MCF-7 cells were treated with 4 µM As2S2 and 1 µM BSO, alone or in combination, for 
72 h, followed by staining with Annexin V/PI, and then analyzed by flow cytometry. MCF-7 
monolayers (A, B) and MCF-7 spheroids (C, D) were assessed for total apoptotic index (see 
Materials and Methods 2-6). All data were expressed as the mean ± SEM (n ≥ 3). Asterisks (*) 
indicate significant differences between the control and the drug treatment groups (*P < 0.05, **P 
< 0.01); Hashes (#) indicate significant differences between the combination and As2S2 alone (##P 
< 0.01). 
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Figure 3-7  Regulatory effects of As2S2 on expression of pro-apoptotic proteins were 
enhanced by co-treatment with BSO in 2D- and 3D-cultured MCF-7 cells.  MCF-7 cells 
were treated with 4 µM As2S2 and 1 µM BSO, alone or in combination, for 72 h. Western blot 
assays were carried out to examine the effects of As2S2 and BSO, alone or in combination, in 2D 
(A-C) and 3D (D-F) culture systems on the expression amounts of pro-apoptotic proteins 
caspase-7 (B and E), and caspase-8 (C and F), respectively. Protein β-actin was used as an internal 
control. All images in A and D are representative of three independent analyses. Bars in B, C, E 
and F indicate means ± SEM (n = 3) of the expression ratio of three independent cellular 
preparations. Asterisks (*) indicate significant differences between the control and the drug 
treatment groups (*P < 0.05, **P < 0.01); Hashes (#) indicate significant differences between the 
combination and As2S2 alone (#P < 0.05, ##P < 0.01).  
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Figure 3-8  Regulatory effects of As2S2 on expression of anti-apoptotic proteins were 
enhanced by co-treatment with BSO in 2D- and 3D-cultured MCF-7 cells.  MCF-7 cells 
were treated with 4 µM As2S2 and 1 µM BSO, alone or in combination, for 72 h. Western blot 
assays were carried out to examine the effects of As2S2 and BSO, alone or in combination, in 2D 
(A-C) and 3D (D-F) culture systems on the expressions of anti-apoptotic proteins Bcl-2 (B and E) 
and Mcl-1 (C and F), respectively. Protein β-actin was used as an internal control. All images in A 
and D are representative of three independent analyses. Bars in B, C, E and F indicate means ± 
SEM (n = 3) of the expression ratio of three independent cellular preparations. Asterisks (*) 
indicate significant differences between the control and the drug treatment groups (*P < 0.05, **P 
< 0.01).  
 
3.4  BSO enhances As2S2 mediated inhibition of pro-survival protein expressions in 2D- and 
3D-cultured MCF-7 cells 
PI3K/Akt pathway contributes to cell survival, growth, and proliferation in carcinomas [106, 
107]. Targeting the regulation of this pro-survival pathway could be a therapeutic strategy for 
cancer treatment. The protein expressions of PI3K and Akt were analyzed in both MCF-7 
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monolayers (2D) and spheroids (3D) by Western blot.  
Figure 3-9A-C shows that As2S2 alone at 4 µM considerably down-regulated expression 
amounts of both PI3K and Akt proteins in MCF-7 monolayers, while the effects were not 
statistically significant. In contrast, combination of As2S2 and BSO elicited a significant inhibition 
on the expression amounts of both PI3K (P = 0.0007) and Akt (P = 0.0068) in 2D-cultured MCF-7 
cells. In 3D-spheroids (Figure 3-9D-F), each agent alone had little inhibitory effect on these 
pro-survival signals, whereas the combination treatment significantly decreased the protein 
expression amounts of both PI3K (P = 0.0154) and Akt (P = 0.0223).  
 
 
Figure 3-9  Regulatory effects of As2S2 on expression of pro-survival proteins were 
enhanced by co-treatment with BSO in 2D- and 3D-cultured MCF-7 cells. MCF-7 cells were 
treated with 4 µM As2S2 and 1 µM BSO, alone or in combination, for 72 h. Western blot assays 
were carried out to examine the effects of As2S2 and BSO, alone or in combination, in both 2D 
(A-C) and 3D (D-F) culture systems on the expressions of pro-survival proteins PI3K (B and E) 
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and Akt (C and F), respectively. Protein β-actin was used as an internal control. All images in A 
and D are representative of three independent analyses. Bars in B, C, E and F indicate means ± 
SEM (n = 3) of the expression ratio of three independent cellular preparations. Asterisks (*) 
indicate significant differences between the control and the drug treatment groups (*P < 0.05, **P 
< 0.01); Hashes (#) indicate significant differences between the combination and As2S2 alone (#P 
< 0.05).  
 
3.5  BSO enhances As2S2 induced inhibition of cellular GSH amounts in 2D- and 3D-cultured 
MCF-7 cells  
Dysregulation of GSH expression has been regarded to contribute to attenuation of cell 
survival and drug-resistance in carcinomas [151, 152]. Thus, targeting manipulation of GSH 
synthesis is an attractive candidate in the treatment of cancerous diseases.  
The intracellular GSH levels were evaluated in both MCF-7 monolayers and spheroids using a 
cellular GSH detection assay kit. As shown in Figure 3-10, As2S2 and BSO in combination 
significantly decreased the cellular GSH levels in both 2D- and 3D-cultured MCF-7 cells (P < 
0.05).  The combination effects were significantly stronger than the effect of each agent alone (P 
< 0.05). Interestingly, BSO alone exerted a significant down-regulation of the cellular GSH level 
in 3D spheroids (P < 0.05), whereas As2S2 alone at 4 M had little effect. Notably, the basal mean 
cellular GSH amount in 3D spheroids (20.4 ± 0.8 µM) was obviously higher than that in 2D 
monolayers (15.3 ± 0.6 µM) without any treatment (P = 0.0001) (data were not shown). 
 
Figure 3-10  Effects of As2S2 and BSO, alone or in combination, on intracellular GSH levels 
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in 2D- and 3D-cultured MCF-7 cells. MCF-7 cells were treated with 4 µM As2S2 and 1 µM BSO, 
alone or in combination, for 72 h. Intracellular GSH amounts of monolayers (2D) and spheroids 
(3D) were detected by using a cellular GSH detection assay kit. Data were presented as mean ± 
SEM (n ≥ 3). &&P < 0.01 vs. 2D; **P < 0.01 vs. control (without As2S2 and BSO); ##P < 0.01 vs. 
each agent alone.  
 
4. DISCUSSION 
In recent decades, 3D cell culture systems have been considered as an attractive approach to 
mimic physiological in vivo cell growth environment and to investigate tumor initiation, 
progression, and metastasis in human carcinomas [53]. In contrast, 2D cell culture system lacks in 
representing the same natural features as 3D system, and is not able to reflect drug sensitivity in 
vivo [78]. However, 2D culture condition can still be accurate for numerous bioactivities, whereas 
the 3D model also has its own shortages [76]. It is recommended that the combination of classical 
2D culture system and novel 3D culture system would be a sensible and important tool to evaluate 
pre-clinical chemotherapies [76]. Therefore, in this Chapter, 2D and 3D models were investigated 
for anticancer efficacies of the combination strategy with As2S2 and BSO against breast cancer 
cells.  
In the previous Chapter I showed that As2S2 decreases cell viability and proliferation, induces 
apoptosis, and arrests cell cycle in human breast cancer cells. However, drug resistance against the 
As2S2 effects was observed especially in 3D cultured cells, which results in a requirement of 
relatively high concentrations of arsenic to achieve a satisfactory antitumor efficacy. In this 
Chapter, a novel combination therapeutic strategy with As2S2 and BSO was proposed to overcome 
the As2S2 resistance in 3D cultured MCF-7 cells.     
It was demonstrated in this Chapter that As2S2 even at relatively low concentration in 
combination with BSO, exhibited a potent inhibitory effect on cell viability and proliferation of 
MCF-7 cells in both 2D- and 3D-models. In addition, the combined use of BSO enhanced other 
anticancer efficacies of As2S2 including apoptosis induction and cell cycle arrest in 2D- and 
3D-cultured MCF-7 cells. The quantitative analyses of the drug combination with As2S2 and BSO 
confirmed the synergistic effects to inhibit the proliferation of MCF-7 cells cultured in both 
monolayers and spheroids (Table 3-1 and 3-2). These results are consistent with the observations 
obtained from combination treatment of BSO with other arsenic compound, arsenic trioxide, in 
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treatment of solid tumors [148, 149].  
   Inhibition of cell viability may correlate to multiple factors including induction of cell cycle 
arrest and apoptosis [153, 154]. Cell cycle arrest at S phase triggered by the combination of As2S2 
at low concentrations and BSO was observed in both MCF-7 monolayers and spheroids, whereas 
As2S2 or BSO alone have no obvious effect in both cell culture systems (Figure 3-4). Furthermore, 
the data from Western blot analysis demonstrated that the synergistic effect of the combination 
treatment on retarding S phase transition was congruent with the down-regulation of cell 
cycle-associated regulator proteins including cyclin A, cyclin B, cyclin D and cdc2 (Figure 3-5). 
In mammalian cells, cyclin A regulates the cell cycle transition from S to G2 phase [155, 156], 
while cyclin D controls cell cycle progression during the G1/S transition [157, 158]. Although 
cyclin B/cdc2 mainly contributes to the G2/M transition, they also play an important role in 
regulating S phase arrest [159, 160]. Besides, the results indicated that co-treatment with As2S2 
and BSO markedly induced apoptosis in both two culture systems, which were not observed in 
either MCF-7 monolayers or spheroids exposed to each agent alone.  
    Combination treatment with As2S2 and BSO activated caspase signals in MCF-7 monolayers. 
Protein expressions of both executioner caspase-7 and initiator caspase-8 significantly increased 
by As2S2 combined with BSO (Figure 3-7A-C). In particular, the synergistic augment of caspase-7 
signal was observed in 2D-cultured MCF-7 cells. Additionally, the enhanced decreases of 
anti-apoptotic proteins, Bcl-2 and Mcl-1, were elicited by the combination treatment (Figure 
3-8A-C). The above phenomenon suggested that co-treatment of As2S2 and BSO enhanced the 
induction of apoptosis in MCF-7 monolayers through both extrinsic and intrinsic pathways, which 
are characterized by regulations of initiator caspase-8 and Bcl-2 family proteins, respectively 
[161-164].  
In contrast, activation of caspases was not observed in MCF-7 spheroids, suggesting that 
apoptosis induction triggered by the combination treatment of As2S2 and BSO in 3D cultured cells 
is mediated by a caspase-independent way. Although countless studies indicated that activation of 
caspases is essential for apoptosis induction, accumulating evidence now ensues that 
caspase-independent mechanism also play an important role in such programmed cell death 
[165-167]. Since cellular characteristics and internal structures of 3D spheroids are quite distinct 
from those of 2D monolayers [168], it is possible that cells cultured in these two different systems 
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underwent apoptosis through different mechanisms. Intriguingly, a significant inhibition of both 
Bcl-2 and Mcl-1 was observed following the combination treatment in MCF-7 spheroids, 
suggesting that proteins in Bcl-2 family are involved in apoptosis induction in the 3D-cultured 
model. Such phenomenon might be associated with activation of a specific caspase-independent 
pathway, which is mediated by regulation of apoptosis inducing factor (AIF) and Bcl-2 family 
members instead of activation of caspases [169]. More investigations are required to disclose the 
underlying mechanisms in relation to caspase-independent pathway that mediate apoptosis 
induction in MCF-7 spheroids.  
   PI3K/Akt signaling pathway is one of the most commonly dysregulated pathways in epithelial 
cancers including breast cancer. It contributes to pro-survival, pro-proliferative and anti-apoptotic 
features of carcinomas, and thus the pathway represents an important target for cancer therapeutic 
strategies [170-172]. The data in this Chapter indicated that neither As2S2 nor BSO alone exhibited 
any inhibitory effect on PI3K and Akt proteins. Conversely, the combination of these two agents 
significantly reduced PI3K/Akt signals in both MCF-7 monolayers and spheroids. Inhibition of 
PI3K/Akt pathway is likely to in turn promote an induction of apoptosis via suppressing the 
anti-apoptotic proteins in Bcl-2 family [173-175], which was also observed in our present study.  
GSH, a ubiquitous intracellular peptide, plays important roles in diverse biological functions 
including anti-oxidant effect, and consequently GSH regulates cell proliferation and contributes to 
drug resistance [176, 177]. My present data showed significant increase in intracellular GSH level 
in MCF-7 spheroids compared with MCF-7 monolayers, suggesting that more potent drug 
resistance occurs in 3D conditions (Figure 3-10). Depletion of intracellular GSH is regarded as 
one of the efficient strategies in the treatment of various malignant diseases. As a specific and 
effective inhibitor of GSH, BSO has been confirmed to inhibit GSH biosynthesis in vitro and in 
vivo [178-180]. Therefore, the significant decrease in GSH levels exerted by BSO in 2D- and 
3D-cultured MCF-7 cells might be the key factor contributes to the synergistic action of BSO in 
potentiating the anticancer effect of As2S2. Importantly, clinical trials showed that BSO alone 
caused a minimal toxicity (occasional nausea/vomiting) when intravenously applied for six doses 
(the maximal dose is 17g/m2) in patients with refractory malignancies [181, 182]. Since the 
concentration of BSO adopted in the present study (1M) was much lower than the safe dose in 
those clinical trials mentioned above, this study may provide the reference to a potential 
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combination therapy for treatment of breast cancer. 
These data of this Chapter, in summary, suggest that As2S2 and BSO in combination 
synergistically decrease intracellular GSH amount and conversely potentiate reactive oxygen 
toxicity in human breast cancer cells, which results in cell cycle arrest, apoptosis induction, and 
cell survival inhibition. Thus, the combination treatment with As2S2 and BSO might be a 
promising therapeutic strategy to increase drug sensitivity of breast cancer cells to As2S2, as well 
as to overcome drug resistance. Importantly, this combination therapy may have significant 
potential for clinical application since both As2S2 and BSO has been already used clinically. 
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GENERAL DISCUSSION AND CONCLUSION 
 
The medicinal use of As2S2 has spanned more than 1800 years. By the late of 20th century, 
As2S2 has been applied clinically to treat leukemia especially for CML and APL [22, 25-27]. 
Similar anti-cancer benefits from As2S2 have been found in solid carcinoma cell lines [33, 34]. 
However, there are few studies concerning the therapeutic efficacies of As2S2 against breast cancer. 
Therefore, the aim of the present study is to investigate the efficacy, toxicity and action 
mechanisms of As2S2 in treatment of breast cancer, using two human breast cancer cell lines.  
   
In Chapter one, a specific focus was introduced concerning the cytotoxic action of As2S2 
against breast cancer MCF-7 cells in both 2D- and 3D-cultured systems, and the mechanism of 
such anticancer action of As2S2 was discussed. The results showed that 3D cultured MCF-7 cells 
exhibit more resistance to the suppressive effects of As2S2 in comparison with 2D cultured cells. 
Moreover, human normal breast epithelial cell line 184B5 and human breast cancer cell line 
MCF-7 were introduced to study the cytotoxic selectivity of As2S2 in different types of breast cells. 
In addition, both 2D and 3D cell cultures were established to proceed with the assessment in a 
broader and more comprehensive view. The results showed that there are significant differences in 
the sensitivities to toxicity of As2S2 between 184B5 and MCF-7 cells in both 2D- and 3D-culture 
systems, confirming that breast cancer cells are more sensitive to As2S2 in comparison with 
normal breast epithelial cells. Especially, two different 3D culture systems based on two distinct 
3D plates (DSeA 3D microplates with TGP and 3D spheroid plates) were introduced in this study 
to evaluate the responses of spheroids to As2S2 exposure in a comprehensive way. The results 
revealed that MCF-7 spheroids established in different 3D culture systems exhibited similar potent 
resistances to the cytotoxicity of As2S2. The data in this Chapter also confirmed the safety of 
As2S2 as a potential anti-breast cancer agent with cytotoxic selectivity.  
 
In Chapter two, the effective action of As2S2 against breast cancer cells was further studied by 
introducing two different breast cancer cell lines MCF-7 and MDA-MB-231. This study 
confirmed the capability of As2S2 to exert the anticancer effects against breast cancer cell line 
MCF-7 in a dose-dependent manner, by inhibiting cell proliferation and inducing apoptosis. In 
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addition, the effects of As2S2 on cell migration and cell cycle progression of MCF-7 cells were 
newly investigated. Importantly, the anticancer actions of As2S2 were further confirmed by using 
another distinct breast cancer cell line MDA-MB-231, suggesting that As2S2 may possess a 
broad-spectrum anticancer efficacies in treatment of different types of breast carcinomas. Such 
anti-cancer functions of As2S2 on MCF-7 and MDA-MB-231 cells were shown to be correlated 
with different molecular alterations, including the regulation of cell invasion-, cell cycle-, 
apoptosis-, and cell survival- related proteins as well as the accumulation of ROS production 
induced by As2S2. In this Chapter, only 2D cell culture system was adopted to obtain a general 
view. The reason is that 2D-cultured approach, with the advantages of being more feasible and 
simple, can still recapitulate in vivo behavior for many bioactivities [76]. However, additional 
studies involving 3D-cultured system are still required in future researches.  
   According to Chapter one and two, the application of As2S2 would be hampered by drug 
resistance of tumor spheroids and water insolubility of the agent, which require high doses of 
As2S2 to achieve its significant efficacy [24]. Combination of different chemotherapeutic agents 
can be an appropriate strategy to potentiate cancer cell susceptibility towards drug exposure, 
overcome chemo-resistance, and reduce the dosage of agents [139, 140].  
 
In Chapter three, the anti-cancer efficacies of As2S2 combined with BSO were investigated 
on MCF-7 cells cultured in 2D- and 3D- systems. The results indicated that As2S2, even at low 
concentrations, when combined with BSO, could significantly induce cell death in MCF-7 cells. 
The possible underlying mechanisms might be associated with the modification of cell cycle- or 
apoptosis-related protein expressions, cellular GSH amounts and PI3K/Akt signals by the 
combination treatment of As2S2 and BSO. The application of this combination strategy may 
benefit to overcome the disadvantages of As2S2 such as drug resistance, arsenic toxicity and low 
solubility in the treatment of breast cancer.  
 
In conclusion, the present study showed that As2S2 might be a potential therapeutic agent in 
the treatment of breast cancer. The data also provided the action mechanisms of the agent, and the 
insights that the combination use of As2S2 with BSO may improve the therapeutic efficacy of 
As2S2 in treatment of drug resistant breast cancer.  
86 
 
REFERENCE 
1. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic 
trioxide. Cancer Res, 62, 3893-3903 (2002) 
2. Ding W, Zhang L, Kim S, Tian W, Tong Y, Liu J, Ma Y, Chen S. Arsenic sulfide as a potential 
anti‑cancer drug. Mol Med Rep, 11, 968-974 (2015) 
3. Liu J, Wei LX, Wang Q, Lu YF, Zhang F, Shi JZ, Li C, Cherian MG. A review of cinnabar 
(HgS) and/or realgar (As4S4)-containing traditional medicines. J Ethnopharmacol, 210, 
340-350 (2018)  
4. Leu L, Mohassel L. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia. 
Am J Health Syst Pharm, 66, 1913-1918 (2009)  
5. Zhang TD. Leukemia treatment in traditional Chinese medicine. J Tradit Chin Med, 10, 13-14 
(1985)  
6. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio 
M, Scheinberg DA, Steinherz P, Sievers EL, Coutré S, Dahlberg S, Ellison R, Warrell RP Jr. 
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. 
J Clin Oncol, 19, 3852-3860 (2001)  
7. Yang MH, Chang KJ, Zheng JC, Huang H, Sun GY, Zhao XW, Li B, Xiu QY. Anti-angiogenic 
effect of arsenic trioxide in lung cancer via inhibition of endothelial cell migration, 
proliferation and tube formation. Oncol Lett, 14, 3103-3109 (2017)  
8. Liu H, Zhang Z, Chi X, Zhao Z, Huang D, Jin J, Gao J. Arsenite-loaded nanoparticles inhibit 
PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells. Sci Rep, 6, 31009 
(2016)  
9. Chow SK, Chan JY, Fung KP. Suppression of cell proliferation and regulation of estrogen 
receptor alpha signaling pathway by arsenic trioxide on human breast cancer MCF‑7 cells. J 
Endocrinol, 182, 325‑337 (2004) 
10. Huang A, Yue D, Liao D, Cheng L, Ma J, Wei Y, Tong A, Cheng P. SurvivinT34A increases 
the therapeutic efficacy of arsenic trioxide in mouse hepatocellular carcinoma models. Oncol 
Rep, 36, 3283-3290 (2016) 
11. Kim Y, Jeong IG, You D, Song SH, Suh N, Jang SW, Kim S, Hwang JJ, Kim CS. Sodium 
meta-arsenite induces reactive oxygen species-dependent apoptosis, necrosis, and autophagy 
87 
 
in both androgen-sensitive and androgen-insensitive prostate cancer cells. Anticancer Drugs, 
25, 53-62 (2014)  
12. Wang H, Liu Y, Wang X, Liu D, Sun Z, Wang C, Jin G, Zhang B, Yu S. Randomized clinical 
control study of locoregional therapy combined with arsenic trioxide for the treatment of 
hepatocellular carcinoma. Cancer, 121, 2917-2925 (2015) 
13. Wu JZ, Ho PC. Comparing the relative oxidative DNA damage caused by various arsenic 
species by quantifying urinary levels of 8-hydroxy-2’-deoxyguanosine with isotope-dilution 
liquid chromatography/mass spectrometry. Pharm Res, 26, 1525-1533 (2009) 
14. Lu DP, Qiu JY, Jiang B, Wang Q, Liu KY, Liu YR, Chen SS. Tetra-arsenic tetra-sulfide for the 
treatment of acute promyelocytic leukemia: a pilot report. Blood, 99, 3136–3143 (2002) 
15. Wu JZ, Ho PC. Evaluation of the in vitro activity and in vivo bioavailability of realgar 
nanoparticles prepared by cryo-grinding. Eur J Pharm Sci, 29, 35-44 (2006)  
16. Chen P, Yan L, Wang Q, Li Y, Li H. Surface alteration of realgar (As4S4) by Acidithiobacillus 
ferrooxidans. Int Microbiol, 15, 9-15 (2012) 
17. Zhang Y, Qiang S, Sun J, Song M, Hang T. Liquid chromatography-hydride generation-atomic 
fluorescence spectrometry determination of arsenic species in dog plasma and its application 
to a pharmacokinetic study after oral administration of Realgar and Niu Huang Jie Du Pian. J 
Chromatogr B Analyt Technol Biomed Life Sci, 917-918, 93-99 (2013)  
18. Baláž P, Sedlák. Arsenic in cancer treatment: challenges for application of realgar 
nanoparticles (a minireview). Toxins (Basel), 2, 1568-1581 (2010) 
19. Balaz P, Choi WS, Dutkova E. Mechanochemical modification of properties and reactivity of 
nanosized arsenic sulfide As4S4. J Phys Chem Solids, 68, 1178–1183 (2007) 
20. Bonazzi P, Bindi L, Pratesi G, Menchetti S. Light-induced changes in molecular arsenic 
sulfides: State of the art and new evidence by single-crystal X-ray diffraction. Am Mineral, 91, 
1323–1330 (2006)  
21. Chen P, Xu R, Yan L, Wu Z, Wei Y, Zhao W, Wang X, Xie Q, Li H. Properties of realgar 
bioleaching using an extremely acidophilic bacterium and its antitumor mechanism as an 
anticancer agent. Biol Res, 50, 17 (2017) 
22. Wu J, Shao Y, Liu J, Chen G, Ho PC. The medicinal use of realgar (As₄S₄) and its recent 
development as an anticancer agent. J Ethnopharmacol, 135, 595-602 (2011) 
88 
 
23. Zhao QH, Zhang Y, Liu Y, Wang HL, Shen YY, Yang WJ, Wen LP. Anticancer effect of 
realgar nanoparticles on mouse melanoma skin cancer in vivo via transdermal drug delivery. 
Med Oncol, 27, 203-212 (2010) 
24. Zhao W, Lu X, Yuan Y, Liu C, Yang B, Hong H, Wang G, Zeng F. Effect of size and 
processing method on the cytotoxicity of realgar nanoparticles in cancer cell lines. Int J 
Nanomedicine, 6, 1569-1577 (2011) 
25. Hu XM, Liu F, Ma R. Application and assessment of Chinese arsenic drugs in treating 
malignant hematopathy in China. Chin J Integr Med, 16, 368-77 (2010) 
26. Zhou AX, Yao BS, Wang K, Wang TE. Effect observation of Qinghuang Powder in treating 
acute non-lymphocytic leukemia. Shanghai J Tradit Chin Med (Chin), 2, 15 (1986) 
27. Huang SL, Guo AX, Xiang Y, Lin HX, Fu L. Clinical study on the treatment of acute 
promyelocytic leukemia mainly with composite Indigo Naturalis Tablets. Chin J Hematol 
(Chin), 16, 26-27 (1995) 
28. Gao XX, Wang XQ, Ma JJ. Treatment of arsenic disulfide in 14 cases with myelodysplastic 
syndrome. J Clin Intern Med (Chin), 5, 125 (1998) 
29. Wang MC, Liu SX, Li XM. Realgar in the treatment for multiple myeloma. J Clin Hematol 
(Chin), 16, 249-251 (2003) 
30. Lu DP, Wang Q. Current study of APL treatment in China. Int J Hematol, Suppl 1, 316-318 
(2002)  
31. Liu R, Pu D, Liu Y, Cheng Y, Yin L, Li T, Zhao L. Induction of SiHa cells apoptosis by 
nanometer realgar suspension and its mechanism. J Huazhong Univ Sci Technolog Med Sci, 
28, 317-321 (2008) 
32. Cheng YX, Liu R, Wang Q, Li BS, Xu XX, Hu M, Chen L, Fu Q, Pu DM, Hong L. 
Realgar-induced apoptosis of cervical cancer cell line Siha via cytochrome c release and 
caspase-3 and caspase-9 activation. Chin J Integr Med, 18, 359-365 (2012)  
33. Song P, Chen P, Wang D, Wu Z, Gao Q, Wang A, Zhu R, Wang Y, Wang X, Zhao L, Duan Z, 
Zhu S, Cui P, Li Y, Li H. Realgar transforming solution displays anticancer potential against 
human hepatocellular carcinoma HepG2 cells by inducing ROS. Int J Oncol, 50, 660-670 
(2017)  
34. Pastorek M, Gronesova P, Cholujova D, Hunakova L, Bujnakova Z, Balaz P, Duraj J, Lee TC, 
89 
 
Sedlak J. Realgar (As4S4) nanoparticles and arsenic trioxide (As2O3) induced autophagy and 
apoptosis in human melanoma cells in vitro. Neoplasma, 61, 700-709 (2014)  
35. Tian Y, Wang X, Xi R, Pan W, Jiang S, Li Z, Zhao Y, Gao G, Liu D. Enhanced antitumor 
activity of realgar mediated by milling it to nanosize. Int J Nanomedicine, 9, 745‑757 (2014) 
36. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and 
prevalence across five continents: Defining priorities to reduce cancer disparities in different 
geographic regions of the world. J Clin Oncol, 24, 2137‑2150 (2006) 
37. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin, 55, 
74-108 (2005)  
38. Breslin S and O'Driscoll L. Three-dimensional cell culture: The missing link in drug discovery. 
Drug Discov Today, 18, 240-249 (2013)  
39. Yamada KM and Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell, 130, 
601‑610 (2007)  
40. Weigelt B, Ghajar CM, Bissell MJ. The need for complex 3D culture models to unravel novel 
pathways and identify accurate biomarkers in breast cancer. Adv Drug Deliv Rev, 69-70, 42‑
51 (2014)  
41. Rimann M, Graf Hausner U. Synthetic 3D multicellular systems for drug development. Curr 
Opin Biotechnol, 23, 803-809 (2012)  
42. Kiyomi A, Makita M, Ozeki T, Li N, Satomura A, Tanaka S, Onda K, Sugiyama K, Iwase T 
and Hirano T. Characterization and clinical implication of Th1/Th2/Th17 cytokines produced 
from three-dimensionally cultured tumor tissues resected from breast cancer patients. Transl 
Oncol, 8, 318‑326 (2015) 
43. Hu XM, Yuan B, Tanaka S, Song MM, Onda K, Tohyama K, Zhou AX, Toyoda H, Hirano T. 
Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic 
syndrome and acute myeloid leukemia cell lines. Hematology, 19, 352-360 (2014)  
44. Ciruelos Gil EM. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor positive 
breast cancer. Cancer Treat Rev, 40, 862-871 (2014) 
45. Tsukikawa S, Matsuoka H, Kurahashi Y, Konno Y, Satoh K, Satoh R, Isogai A, Kimura K, 
Watanabe Y, Nakano S, Hayashi J, Kubota S. A new method to prepare multicellular spheroids 
in cancer cell lines using a thermo reversible gelation polymer. Artif Organs, 27, 598-604 
90 
 
(2003) 
46. Khaitan D, Chandna S, Arya MB, Dwarakanath BS. Establishment and characterization of 
multicellular spheroids from a human glioma cell line; Implications for tumor therapy. J 
Transl Med, 4, 12 (2006) 
47. Edmondson R, Broglie JJ, Adcock AF, Yang L. Three dimensional cell culture systems and 
their applications in drug discovery and cell based biosensors. Assay Drug Dev Technol, 12, 
207-218 (2014) 
48. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehart JD. NF-kappa B 
activation in human breast cancer specimens and its role in cell proliferation and apoptosis. 
Proc Natl Acad Sci USA, 101, 10137-10142 (2004) 
49. Vermeulen K, Berneman ZN, Van Bockstaele DR. Cell cycle and apoptosis. Cell Prolif, 36, 
165-175 (2003) 
50. Fischbach C, Chen R, Matsumoto T, Schmelzle T, Brugge JS, Polverini PJ, Mooney DJ. 
Engineering tumors with 3D scaffolds. Nat Methods, 4, 855-860 (2007) 
51. Debnath J, Brugge JS. Modelling glandular epithelial cancers in three dimensional cultures. 
Nat Rev Cancer, 5, 675-688 (2005) 
52. Zeng H, Sun M, Zhou C, Yin F, Wang Z, Hua Y, Cai Z. Hematoporphyrin monomethyl ether 
mediated photodynamic therapy selectively kills sarcomas by inducing apoptosis. PLoS One, 
8, e77727 (2013) 
53. Akeda K, Nishimura A, Satonaka H, Shintani K, Kusuzaki K, Matsumine A, Kasai Y, Masuda 
K, Uchida A. Three dimensional alginate spheroid culture system of murine osteosarcoma. 
Oncol Rep, 22, 997-1003 (2009) 
54. Chandrasekaran S, Marshall JR, Messing JA, Hsu JW, King MR. TRAIL mediated apoptosis 
in breast cancer cells cultured as 3D spheroids. PLoS One, 9, e111487 (2014) 
55. Sodek KL, Murphy KJ, Brown TJ, Ringuette MJ. Cell-cell and cell-matrix dynamics in 
intraperitoneal cancer metastasis. Cancer Metastasis Rev, 31, 397-414 (2012) 
56. Daubriac J, Fleury Feith J, Kheuang L, Galipon J, Saint Albin A, Renier A, Giovannini M, 
Galateau Sallé F, Jaurand MC. Malignant pleural mesothelioma cells resist anoikis as 
quiescent pluricellular aggregates. Cell Death Differ, 16, 1146-1155 (2009) 
57. Khairul I, Wang QQ, Jiang YH, Wang C, Naranmandura H. Metabolism, toxicity and 
91 
 
anticancer activities of arsenic compounds. Oncotarget, 8, 23905-23926 (2017) 
58. Boehme KA, Nitsch J, Riester R, Handgretinger R, Schleicher SB, Kluba T, Traub F. Arsenic 
trioxide potentiates the effectiveness of etoposide in Ewing sarcomas. Int J Oncol, 49, 
2135-2146 (2016) 
59. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, 
substrates, and functions during apoptosis. Annu Rev Biochem, 68, 383-424 (1999) 
60. Kadam CY, Abhang SA. Apoptosis Markers in Breast Cancer Therapy. Adv Clin Chem, 74, 
143-193 (2016) 
61. Kurokawa H, Nishio K, Fukumoto H, Tomonari A, Suzuki T, Saijo N. Alteration of caspase 3 
(CPP32/Yama/apopain) in wild type MCF 7, breast cancer cells. Oncol Rep, 6, 33-37 (1999) 
62. Simstein R, Burow M, Parker A, Weldon C, Beckman B. Apoptosis, chemoresistance, and 
breast cancer: insights from the MCF-7 cell model system. Exp Biol Med (Maywood), 228, 
995-1003 (2003) 
63. Wang X, Simpson ER, Brown KA. p53: Protection against Tumor Growth beyond Effects on 
Cell Cycle and Apoptosis. Cancer Res, 75, 5001-5007 (2015) 
64. Pietsch EC, Sykes SM, McMahon SB, Murphy ME. The p53 family and programmed cell 
death. Oncogene, 27, 6507-6521 (2008) 
65. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of 
activation and therapeutic targeting. Nat Rev Cancer, 15, 7-24 (2015) 
66. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3 kinase 
pathway: role in tumor progression and therapeutic implications in breast cancer. Breast 
Cancer Res, 13, 224 (2011) 
67. Lu YF, Wu Q, Yan JW, Shi JZ, Liu J, Shi JS. Realgar, cinnabar and An-Gong-Niu-Huang Wan 
are much less chronically nephrotoxic than common arsenicals and mercurials. Exp Biol Med 
(Maywood), 236, 233-239 (2011)  
68. Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang JX, Jiang H, Chen SJ, Huang XJ. Oral tetra-arsenic 
tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute 
promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol, 31, 
4215-4221 (2013) 
69. Li XX, Wang LQ, Li H, He XP, Li FL, Wang LL, Chen XL, Hou M. Clinical study on 
92 
 
prospective efficacy of all-trans Acid, realgar-indigo naturalis formula combined with 
chemotherapy as maintenance treatment of acute promyelocytic leukemia. Evid Based 
Complement Alternat Med, 2014, 987560 (2014)  
70. Mao JH, Sun XY, Liu JX, Zhang QY, Liu P, Huang QH, Li KK, Chen Q, Chen Z, Chen SJ. 
As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic 
myelogenous leukemia. Proc Natl Acad Sci U S A, 107, 21683-21688 (2010)  
71. Zhang X, Xie QJ, Wang X, Wang B, Li HY. Biological extraction of realgar by 
Acidithiobacillus ferrooxidans and its in vitro and in vivo antitumor activities. Pharm Biol, 48, 
40-47 (2010) 
72. Wang H, Liu Z, Gou Y, Qin Y, Xu Y, Liu J, Wu JZ. Apoptosis and necrosis induced by novel 
realgar quantum dots in human endometrial cancer cells via endoplasmic reticulum stress 
signaling pathway. Int J Nanomedicine, 10, 5505-5512 (2015) 
73. Qin Y, Wang H, Liu ZY, Liu J, Wu JZ. Realgar quantum dots induce apoptosis and necrosis in 
HepG2 cells through endoplasmic reticulum stress. Biomed Rep 3, 657-662 (2015) 
74. Dubois V, Jardé T, Delort L, Billard H, Bernard‑Gallon D, Berger E, Geloen A, Vasson MP 
and Caldefie‑Chezet F. Leptin induces a proliferative response in breast cancer cells but not in 
normal breast cells. Nutr Cancer, 66, 645‑655 (2014)  
75. Alcolea V, Plano D, Encío I, Palop JA, Sharma AK and Sanmartín C. Chalcogen containing 
heterocyclic scaffolds: New hybrids with antitumoral activity. Eur J Med Chem, 123, 407‑418 
(2016)  
76. Duval K, Grover H, Han LH, Mou Y, Pegoraro AF, Fredberg J, Chen Z. Modeling 
Physiological Events in 2D vs. 3D Cell Culture. Physiology (Bethesda), 32, 266-277 (2017)  
77. Breslin S, O'Driscoll L. The relevance of using 3D cell cultures, in addition to 2D monolayer 
cultures, when evaluating breast cancer drug sensitivity and resistance. Oncotarget, 7, 
45745-45756 (2016) 
78. Imamura Y, Mukohara T, Shimono Y, Funakoshi Y, Chayahara N, Toyoda M, Kiyota N, Takao 
S, Kono S, Nakatsura T, Minami H. Comparison of 2D- and 3D-culture models as 
drug-testing platforms in breast cancer. Oncol Rep, 33, 1837-1843 (2015)  
79. Hoarau-Véchot J, Rafii A, Touboul C, Pasquier J. Halfway between 2D and Animal Models: 
Are 3D Cultures the Ideal Tool to Study Cancer-Microenvironment Interactions? Int J Mol Sci, 
93 
 
19, E181 (2018)  
80. Oral AY, Cevatemre B, Sarimahmut M, Icsel C, Yilmaz VT, Ulukaya E. Anti-growth effect of 
a novel trans-dichloridobis[2-(2-hydroxyethyl)pyridine]platinum (II) complex via induction of 
apoptosis on breast cancer cell lines. Bioorg Med Chem, 23, 4303-4310 (2015) 
81. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an 
update. Breast Cancer Res Treat, 83, 249-289 (2004). 
82. Hunakova L, Macejova D, Toporova L, Brtko J. Anticancer effects of tributyltin chloride and 
triphenyltin chloride in human breast cancer cell lines MCF-7 and MDA-MB-231. Tumour 
Biol, 37, 6701-6708 (2016) 
83. Hasanpourghadi M, Pandurangan AK, Mustafa MR. Modulation of oncogenic transcription 
factors by bioactive natural products in breast cancer. Pharmacol Res, S1043-6618, 
30864-30872 (2017) 
84. Pasqualini JR, Schatz B, Varin C, Nguyen BL. Recent data on estrogen sulfatases and 
sulfotransferases activities in human breast cancer. J Steroid Biochem Mol Biol, 41, 323-329 
(1992) 
85. Wang X, Zhang X, Xu Z, Wang Z, Yue X, Li H. Reversal effect of arsenic sensitivity in 
human leukemia cell line K562 and K562/ADM using realgar transforming solution. Biol 
Pharm Bull, 36, 641-648 (2013) 
86. Xie QJ, Cao XL, Bai L, Wu ZR, Ma YP, Li HY. Anti-tumor effects and apoptosis induction by 
Realgar bioleaching solution in Sarcoma-180 cells in vitro and transplanted tumors in mice in 
vivo. Asian Pac J Cancer Prev, 15, 2883-2888 (2014) 
87. Engelberg-Kulka H, Amitai S, Kolodkin-Gal I, Hazan R. Bacterial programmed cell death and 
multicellular behavior in bacteria. PLoS Genet, 2, e135 (2006)  
88. Fuchs Y, Steller H. Programmed cell death in animal development and disease. Cell, 147, 
742-758 (2011) 
89. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between 
autophagy and apoptosis. Nat Rev Mol Cell Biol, 8, 741-752 (2007) 
90. Booth LA, Tavallai S, Hamed HA, Cruickshanks N, Dent P. The role of cell signaling in the 
crosstalk between autophagy and apoptosis. Cell Signal, 26, 549-555 (2014)  
91. Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. 
94 
 
Pharmacol Ther, 92, 57-70 (2001) 
92. Levine B, Deretic V. Unveiling the roles of autophagy in innate and adaptive immunity. Nat 
Rev Immunol, 7, 767-777 (2007) 
93. Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A. Life and death partners: apoptosis, 
autophagy and the cross-talk between them. Cell Death Differ, 16, 966-975 (2009) 
94. Zambrano J, Yeh ES. Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic 
Resistance in HER2-Positive Breast Cancer. Breast Cancer (Auckl), 10, 13-23 (2016) 
95. Shi D, Liu Y, Xi R, Zou W, Wu L, Zhang Z, Liu Z, Qu C, Xu B, Wang X. Caveolin-1 
contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 
cells. Int J Nanomedicine, 11, 5823-5835 (2016)  
96. Shi X, Zhang Y, Zheng J, Pan J. Reactive oxygen species in cancer stem cells. Antioxid Redox 
Signal, 16, 1215-1228 (2012)  
97. Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB. Upsides and downsides of 
reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, 
prevention, and therapy. Antioxid Redox Signal, 16, 1295–1322 (2012) 
98. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: 
a radical therapeutic approach? Nat Rev Drug Discov, 8, 579–591 (2009) 
99. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively 
induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent 
pathway. Blood, 94, 2102-2111 (1999) 
100. Chen YC, Lin-Shiau SY, Lin JK. Involvement of reactive oxygen species and caspase-3 
activation in arsenite-induced apoptosis. J Cell Physiol, 177, 324-333 (1998) 
101. Maeda H, Hori S, Nishitoh H, Ichijo H, Ogawa O, Kakehi Y, Kakizuka A. Tumor growth 
inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of 
androgen-independent prostate cancer. Cancer Res, 61, 5432-5440 (2001) 
102. Jayakumar AR, Bak LK, Rama Rao KV, Waagepetersen HS, Schousboe A, Norenberg MD. 
Neuronal Cell Death Induced by Mechanical Percussion Trauma in Cultured Neurons is not 
Preceded by Alterations in Glucose, Lactate and Glutamine Metabolism. Neurochem Res, 41, 
307-315 (2016)  
103. Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, Bao JK. Programmed cell death 
95 
 
pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif, 
45, 487-498 (2012)  
104. Li Y, Chang Y, Ye N, Dai D, Chen Y, Zhang N, Sun G, Sun Y. Advanced Glycation End 
Products Inhibit the Proliferation of Human Umbilical Vein Endothelial Cells by Inhibiting 
Cathepsin D. Int J Mol Sci, 18, 1-19 (2017) 
105. Aparicio IM, Martin Muñoz P, Salido GM, Peña FJ, Tapia JA. The autophagy-related protein 
LC3 is processed in stallion spermatozoa during short-and long-term storage and the related 
stressful conditions. Animal, 10, 1182-1191 (2016)  
106. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature, 
441, 424-430 (2006)  
107. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: 
rationale and promise. Cancer Cell, 4, 257-262 (2003) 
108. Singh BN, Singh HB, Singh A, Naqvi AH, Singh BR. Dietary phytochemicals alter 
epigenetic events and signaling pathways for inhibition of metastasis cascade: phytoblockers 
of metastasis cascade. Cancer Metastasis Rev, 33, 41-85 (2014) 
109. Zhou J, Zhu YF, Chen XY, Han B, Li F, Chen JY, Peng XL, Luo LP, Chen W, Yu XP. Black 
rice-derived anthocyanins inhibit HER-2-positive breast cancer epithelial-mesenchymal 
transition-mediated metastasis in vitro by suppressing FAK signaling. Int J Mol Med, 40, 
1649-1656 (2017) 
110. Si L, Yan X, Hao W, Ma X, Ren H, Ren B, Li D, Dong Z, Zheng Q. Licochalcone D induces 
apoptosis and inhibits migration and invasion in human melanoma A375 cells. Oncol Rep, 39, 
2160-2170 (2018) 
111. Jacob A, Prekeris R. The regulation of MMP targeting to invadopodia during cancer 
metastasis. Front Cell Dev Biol, 3, 4 (2015) 
112. Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A, Cascante M. Targeting cell cycle 
regulation in cancer therapy. Pharmacol Ther, 138, 255-271 (2013) 
113. Stewart ZA, Westfall MD, Pietenpol JA. Cell-cycle dysregulation and anticancer therapy. 
Trends Pharmacol Sci, 24, 139-145 (2003) 
114. Marconett CN, Morgenstern TJ, San Roman AK, Sundar SN, Singhal AK, Firestone GL. 
BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of 
96 
 
human breast and prostate cancer cells through distinct mechanisms dependent on the cancer 
cell phenotype. Cancer Biol Ther, 10, 397-405 (2010) 
115. Sim MY, Go ML, Yuen JSP. The mechanistic effects of the dioxonaphthoimidazolium analog 
YM155 in renal cell carcinoma cell cycling and apoptosis. Life Sci, 203, 282-290 (2018)  
116. Mariño G, Niso-Santano M, Baehrecke EH, Kroemer G. Self-consumption: the interplay of 
autophagy and apoptosis. Nat Rev Mol Cell Biol, 15, 81-94 (2014) 
117. Ricci MS, Zong WX. Chemotherapeutic approaches for targeting cell death pathways. 
Oncologist, 11, 342-357 (2006) 
118. Suen DF, Norris KL, Youle RJ. Mitochondrial dynamics and apoptosis. Genes Dev, 22, 
1577-1590 (2008) 
119. Dickens LS, Boyd RS, Jukes-Jones R, Hughes MA, Robinson GL, Fairall L, Schwabe JW, 
Cain K, Macfarlane M. A death effector domain chain DISC model reveals a crucial role for 
caspase-8 chain assembly in mediating apoptotic cell death. Mol Cell, 47, 291-305 (2012) 
120. Martinou JC, Youle RJ. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial 
dynamics. Dev Cell, 21, 92-101 (2011) 
121. Pettersson F, Dalgleish AG, Bissonnette RP, Colston KW. Retinoids cause apoptosis in 
pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax. Br 
J Cancer, 87, 555-561 (2002) 
122. Liu F, Gao S, Yang Y, Zhao X, Fan Y, Ma W, Yang D, Yang A, Yu Y. Curcumin induced 
autophagy anticancer effects on human lung adenocarcinoma cell line A549. Oncol Lett, 14, 
2775-2782 (2017) 
123. Kim KY, Park KI, Kim SH, Yu SN, Park SG, Kim YW, Seo YK, Ma JY, Ahn SC. Inhibition 
of Autophagy Promotes Salinomycin-Induced Apoptosis via Reactive Oxygen 
Species-Mediated PI3K/AKT/mTOR and ERK/p38 MAPK-Dependent Signaling in Human 
Prostate Cancer Cells. Int J Mol Sci, 18, E1088 (2017) 
124. Tang F, Wang B, Li N, Wu Y, Jia J, Suo T, Chen Q, Liu YJ, Tang J. RNF185, a novel 
mitochondrial ubiquitin E3 ligase, regulates autophagy through interaction with BNIP1. PLoS 
One, 6, e24367 (2011) 
125. Li Y, Cui Y, Wang W, Ma M, Li M, Chen S. Effect of the Serum Inhibited Gene (Si1) on 
Autophagy and Apoptosis in MCF-7 Breast Cancer Cells. Cell Physiol Biochem, 41, 
97 
 
2268-2278 (2017) 
126. Zeng Y, Li S, Wu J, Chen W, Sun H, Peng W, Yu X, Yang X. Autophagy inhibitors promoted 
aristolochic acid I induced renal tubular epithelial cell apoptosis via mitochondrial pathway 
but alleviated nonapoptotic cell death in mouse acute aritolochic acid nephropathy model. 
Apoptosis, 19, 1215-1224 (2014) 
127. Subramani R, Gonzalez E, Arumugam A, Nandy S, Gonzalez V, Medel J, Camacho F, Ortega 
A, Bonkoungou S, Narayan M, Dwivedi Ak, Lakshmanaswamy R. Nimbolide inhibits 
pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of 
epithelial-to-mesenchymal transition. Sci Rep, 6, 19819 (2016) 
128. Wang L, Li P, Hu W, Xia Y, Hu C, Liu L, Jiang X. CD44+CD24+ subset of PANC-1 cells 
exhibits radiation resistance via decreased levels of reactive oxygen species. Oncol Lett, 14, 
1341-1346 (2017) 
129. Banerjee A, Banerjee V, Czinn S, Blanchard T. Increased reactive oxygen species levels cause 
ER stress and cytotoxicity in andrographolide treated colon cancer cells. Oncotarget, 8, 
26142–26153 (2017) 
130. Li B, Zhao S, Geng R, Huo Z, Zhang H. The Sineoculis Homeobox Homolog 1 (SIX1) Gene 
Regulates Paclitaxel Resistance by Affecting Reactive Oxygen Species and Autophagy in 
Human Hepatocellular Carcinoma Cell Line HepG2. Med Sci Monit, 24, 2271-2279 (2018) 
131. Apel K, Hirt H. Reactive oxygen species: Metabolism, oxidative stress, and signal 
transduction. Annu Rev Plant Biol, 55, 373-399 (2004) 
132. Li L, Cao W, Zheng W, Fan C, Chen T. Ruthenium complexes containing 
2,6-bis(benzimidazolyl)pyridine derivatives induce cancer cell apoptosis by triggering DNA 
damage-mediated p53 phosphorylation. Dalton Trans, 41, 12766-12772 (2012) 
133. Benhar M, Engelberg D, Levitzki A. ROS, stress-activated kinases and stress signaling in 
cancer. EMBO Rep, 3, 420-425 (2002) 
134. Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Mol 
Biosyst, 11, 1946-1954 (2015) 
135. Lanuza PM, Vigueras A, Olivan S, Prats AC, Costas S, Llamazares G, Sanchez-Martinez D, 
Ayuso JM, Fernandez L, Ochoa I, Pardo J. Activated human primary NK cells efficiently kill 
colorectal cancer cells in 3D spheroid cultures irrespectively of the level of PD-L1 expression. 
98 
 
Oncoimmunology, 7, e1395123 (2018) 
136. Lv D, Yu SC, Ping YF, Wu H, Zhao X, Zhang H, Cui Y, Chen B, Zhang X, Dai J, Bian XW, 
Yao XH. A three-dimensional collagen scaffold cell culture system for screening anti-glioma 
therapeutics. Oncotarget, 7, 56904-56914 (2016) 
137. Chen L, Xiao Z, Meng Y, Zhao Y, Han J, Su G, Chen B, Dai J. The enhancement of cancer 
stem cell properties of MCF-7 cells in 3D collagen scaffolds for modeling of cancer and 
anti-cancer drugs. Biomaterials, 33, 1437-1444 (2012) 
138. Liu D, Zhi D, Zhou T, Yu Q, Wan F, Bai Y, Li H. Realgar bioleaching solution is a less toxic 
arsenic agent in suppressing the Ras/MAPK pathway in Caenorhabditis elegans. Environ 
Toxicol Pharmacol, 35, 292-299 (2013) 
139. Garbutcheon-Singh KB, Harper BW, Myers S, Aldrich-Wright JR. Combination studies of 
platinum(II)-based metallointercalators with buthionine-S,R-sulfoximine, 3-bromopyruvate, 
cisplatin or carboplatin. Metallomics, 6, 126-131 (2014) 
140. Marostica LL, Silva IT, Kratz JM, Persich L, Geller FC, Lang KL, Caro MS, Durán FJ, 
Schenkel EP, Simões CM. Synergistic Antiproliferative Effects of a New Cucurbitacin B 
Derivative and Chemotherapy Drugs on Lung Cancer Cell Line A549. Chem Res Toxicol, 28, 
1949-1960 (2015) 
141. Zhang QY, Mao JH, Liu P, Huang QH, Lu J, Xie YY, Weng L, Zhang Y, Chen Q, Chen SJ, 
Chen Z. A systems biology understanding of the synergistic effects of arsenic sulfide and 
Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A, 106, 3378-3383 (2009) 
142. Liu N, Tai S, Ding B, Thor RK, Bhuta S, Sun Y, Huang J. Arsenic trioxide synergizes with 
everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased 
autophagy and apoptosis. Endocr Relat Cancer, 19, 711-723 (2012) 
143. Zhang YF, Zhang M, Huang XL, Fu YJ, Jiang YH, Bao LL, Maimaitiyiming Y, Zhang GJ, 
Wang QQ, Naranmandura H. The combination of arsenic and cryptotanshinone induces 
apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in breast 
cancer cells. Metallomics, 7, 165-173 (2015) 
144. Bailey HH. L-S,R-buthionine sulfoximine: historical development and clinical issues. Chem 
Biol Interact, 111-112, 239-254 (1998) 
145. Li L, Fath MA, Scarbrough PM, Watson WH, Spitz DR. Combined inhibition of glycolysis, 
99 
 
the pentose cycle, and thioredoxin metabolism selectively increases cytotoxicity and oxidative 
stress in human breast and prostate cancer. Redox Biol, 4, 127-135 (2015) 
146. Li Q, Yin X, Wang W, Zhan M, Zhao B, Hou Z, Wang J. The effects of buthionine 
sulfoximine on the proliferation and apoptosis of biliary tract cancer cells induced by cisplatin 
and gemcitabine. Oncol Lett, 11, 474-480 (2016) 
147. Cuperus R, van Kuilenburg AB, Leen R, Bras J, Caron HN, Tytgat GA. Promising effects of 
the 4HPR-BSO combination in neuroblastoma monolayers and spheroids. Free Radic Biol 
Med, 51, 1213-1220 (2011) 
148. Tanaka Y, Komatsu T, Shigemi H, Yamauchi T, Fujii Y. BIMEL is a key effector molecule in 
oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with 
arsenic trioxide and buthionine sulfoximine. BMC Cancer, 14, 27 (2014) 
149. Maeda H, Hori S, Ohizumi H, Segawa T, Kakehi Y, Ogawa O, Kakizuka A. Effective 
treatment of advanced solid tumors by the combination of arsenic trioxide and 
L-buthionine-sulfoximine. Cell Death Differ, 11, 737-746 (2004) 
150. Chou TC, Talaly P. A simple generalized equation for the analysis of multiple inhibitions of 
Michaelis-Menten kinetic systems. J Biol Chem, 252, 6438-6442 (1977) 
151. Lu SC. Regulation of glutathione synthesis. Mol Aspects Med, 30, 42-59 (2009) 
152. Chowdhury AA, Chaudhuri J, Biswas N, Manna A, Chatterjee S, Mahato SK, Chaudhuri U, 
Jaisankar P, Bandyopadhyay S. Synergistic apoptosis of CML cells by buthionine sulfoximine 
and hydroxychavicol correlates with activation of AIF and GSH-ROS-JNK-ERK-iNOS 
pathway. PLoS One, 8, e73672 (2013) 
153. Zhang H, Tian Y, Zhu Z, Xu H, Li X, Zheng D, Sun W. Efficient antitumor effect of 
co-drug-loaded nanoparticles with gelatin hydrogel by local implantation. Sci Rep, 6, 26546 
(2016) 
154. O'Connor L, Huang DC, O'Reilly LA, Strasser A. Apoptosis and cell division. Curr Opin 
Cell Biol, 12, 257-263 (2000) 
155. Gérard C, Goldbeter A. From quiescence to proliferation: Cdk oscillations drive the 
mammalian cell cycle. Front Physiol, 3, 413 (2012) 
156. Mai L, Yi F, Gou X, Zhang J, Wang C, Liu G, Bu Y, Yuan C, Deng L, Song F. The 
overexpression of MCPH1 inhibits cell growth through regulating cell cycle-related proteins 
100 
 
and activating cytochrome c-caspase 3 signaling in cervical cancer. Mol Cell Biochem, 392, 
95-107 (2014) 
157. Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol Ther, 1, 226-231 (2002) 
158. Itoh T, Ono A, Kawaguchi K, Teraoka S, Harada M, Sumi K, Ando M, Tsukamasa Y, 
Ninomiya M, Koketsu M, Hashizume T. Phytol isolated from watermelon (Citrullus lanatus) 
sprouts induces cell death in human T-lymphoid cell line Jurkat cells via S-phase cell cycle 
arrest. Food Chem Toxicol, 115, 425-435 (2018) 
159. Zineldeen DH, Shafik NM, Li SF. Alternative Chk1-independent S/M checkpoint in somatic 
cells that prevents premature mitotic entry. Med Oncol, 34, 70 (2017) 
160. Li L, Chen X, Liu CC, Lee LS, Man C, Cheng SH. Phytoestrogen Bakuchiol Exhibits In 
Vitro and In Vivo Anti-breast Cancer Effects by Inducing S Phase Arrest and Apoptosis. Front 
Pharmacol, 7, 128 (2016) 
161. Pfeffer CM, Singh ATK. Apoptosis: A Target for Anticancer Therapy. Int J Mol Sci, 19, E448 
(2018) 
162. Green DR, Llambi F. Cell Death Signaling. Cold Spring Harb Perspect Biol, 7, a006080 
(2015) 
163. Zaman S, Wang R, Gandhi V. Targeting the apoptosis pathway in hematologic malignancies. 
Leuk Lymphoma, 55, 1980-1992 (2014) 
164. Kalkavan H, Green DR. MOMP, cell suicide as a BCL-2 family business. Cell Death Differ, 
25, 46-55 (2018) 
165. Broughton BR, Reutens DC, Sobey CG. Apoptotic mechanisms after cerebral ischemia. 
Stroke, 40, e331-339 (2009) 
166. Tait SW, Green DR. Caspase-independent cell death: leaving the set without the final cut. 
Oncogene, 27, 6452-6461 (2008) 
167. Kitanaka C, Kuchino Y. Caspase-independent programmed cell death with necrotic 
morphology. Cell Death Differ, 6, 508-515 (1999) 
168. Costa EC, Moreira AF, de Melo-Diogo D, Gaspar VM, Carvalho MP, Correia IJ. 3D tumor 
spheroids: an overview on the tools and techniques used for their analysis. Biotechnol Adv, 34, 
1427-1441 (2016) 
169. Cho BB, Toledo-Pereyra LH. Caspase-independent programmed cell death following 
101 
 
ischemic stroke. J Invest Surg, 21, 141-147 (2008) 
170. Park S, Bazer FW, Lim W, Song G. The O-methylated isoflavone, formononetin, inhibits 
human ovarian cancer cell proliferation by sub G0/G1 cell phase arrest through PI3K/AKT 
and ERK1/2 inactivation. J Cell Biochem, 119, 7377-7387 (2018)  
171. Lien EC, Lyssiotis CA, Juvekar A, Hu H, Asara JM, Cantley LC, Toker A. Glutathione 
biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer. Nat Cell Biol, 18, 
572-578 (2016) 
172. De Wolf E, De Wolf C, Richardson A. ABT-737 and pictilisib synergistically enhance 
pitavastatin-induced apoptosis in ovarian cancer cells. Oncol Lett, 15, 1979-1984 (2018) 
173. Xia LJ, Wu YL, Zhang FC. Combination of cecropinXJ and LY294002 induces synergistic 
cytotoxicity, and apoptosis in human gastric cancer cells via inhibition of the PI3K/Akt 
signaling pathway. Oncol Lett, 14, 7522-7528 (2017) 
174. Han Z, Hong L, Han Y, Wu K, Han S, Shen H, Li C, Yao L, Qiao T, Fan D. Phospho Akt 
mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and 
Bax. J Exp Clin Cancer Res, 26, 261-268 (2007) 
175. Lee WS, Yi SM, Yun JW, Jung JH, Kim DH, Kim HJ, Chang SH, Kim G, Ryu CH, Shin SC, 
Hong SC, Choi YH, Jung JM. Polyphenols Isolated from Allium cepa L. Induces Apoptosis 
by Induction of p53 and Suppression of Bcl-2 through Inhibiting PI3K/Akt Signaling Pathway 
in AGS Human Cancer Cells. J Cancer Prev, 19, 14-22 (2014) 
176. Vázquez C, Mejia-Tlachi M, González-Chávez Z, Silva A, Rodríguez-Zavala JS, 
Moreno-Sánchez R, Saavedra E. Buthionine sulfoximine is a multitarget inhibitor of 
trypanothione synthesis in Trypanosoma cruzi. FEBS Lett, 591, 3881-3894 (2017) 
177. Tokumoto M, Lee JY, Shimada A, Tohyama C, Satoh M. Glutathione has a more important 
role than metallothionein-I/II against inorganic mercury-induced acute renal toxicity. J Toxicol 
Sci, 43, 275-280 (2018) 
178. Andrews PA, Murphy MP, Howell SB. Differential potentiation of alkylating and platinating 
agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res, 45, 
6250-6253 (1985) 
179. Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC. Enhanced 
melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by 
102 
 
buthionine sulfoximine depletion of glutathione. Biochem Pharmacol, 36, 147-153 (1987) 
180. Somfai-Relle S, Suzukake K, Vistica BP, Vistica DT. Reduction in cellular glutathione by 
buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine 
mustard. Biochem Pharmacol, 33, 485-490 (1984) 
181. Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, 
Pomplun M, Spriggs DR. Phase I clinical trial of intravenous L-buthionine sulfoximine and 
melphalan: an attempt at modulation of glutathione. J Clin Oncol, 12, 194-205 (1994) 
182. O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, 
Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF. Phase I trial of buthionine 
sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol, 14, 249-256 
(1996)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
103 
 
ACKNOWLEDGMENTS 
 
Firstly, I would like to express my sincere gratitude to my supervisor Professor Toshihiko 
Hirano for the continuous support of my PhD study and related research, for his patience, 
motivation, and immense knowledge. His guidance helped me in all the time of research and 
writing of this thesis. I could not have imagined having a better advisor and mentor for my PhD 
study.  
Besides my supervisor, I would like to thank the faculty in Department of Clinical 
Pharmacology, School of Pharmacy: Dr. Kentaro Sugiyama, Dr. Kenji Onda, and Dr. Sachiko 
Tanaka, for their steady support, generous help, sound advice, and warm encouragement.  
My sincere thanks also go to Dr. Bo Yuan from Department of Applied Biochemistry, School 
of Pharmacy, for his generous help, considerable expertise, and insightful comments during the 
entire process.  
I would also like to thank Dr. Anna Kiyomi from Department of Drug Safety and Risk 
Management, School of Pharmacy, for her kind help during the experiment.  
In particular, I am grateful to Professor Haruki Yamada in Department of Kampo Medicines, 
School of Pharmacy, for his inspiring encouragement and constructive advice.  
I thank my fellow lab-mates, all of the students in Department of Clinical Pharmacology, for 
their kind assistance, technical guidance, and for all the fun we have had in the last two years.  
I would like to express my thanks to Tokyo University of Pharmacy and Life Sciences and 
China Academy of Chinese Medical Sciences for providing me such a precious opportunity.  
I also sincere thank the China Scholarship Council (File No. 201709110064) for supporting 
me in the second year. 
Last but not the least, I would like to thank my family: my parents and my husband for 
supporting me spiritually throughout writing this thesis and my life in general.  
 
 
